
<html lang="en"     class="pb-page"  data-request-id="092845c7-5ee6-42a9-a6bd-a766e1f2a868"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-10;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01310;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Lingfeng  Chen" /></meta><meta name="dc.Creator" content="Weitao  Fu" /></meta><meta name="dc.Creator" content="Lulu  Zheng" /></meta><meta name="dc.Creator" content="Zhiguo  Liu" /></meta><meta name="dc.Creator" content="Guang  Liang" /></meta><meta name="dc.Description" content="The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule..." /></meta><meta name="Description" content="The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 14, 2017" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01310" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01310" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01310" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01310" /></link>
        
    
    

<title>Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01310" /></meta><meta property="og:title" content="Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0009.jpeg" /></meta><meta property="og:description" content="The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule inhibitors, especially osimertinib, are at the forefront clinically for treatment of patients with NSCLC. However, a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 (C797S) mutation in the EGFR kinase domain. This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs. In this Miniperspective, we present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance. Specifically, we analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations. Lastly, we provide some perspectives on new challenges and future directions in this field." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01310"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01310">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01310&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01310&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01310&amp;href=/doi/10.1021/acs.jmedchem.7b01310" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4290-4300</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01120" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.7b01627" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Lingfeng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lingfeng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</div><div class="loa-info-affiliations-info">School of Chemical Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu 210094, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lingfeng++Chen">Lingfeng Chen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weitao Fu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weitao Fu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weitao++Fu">Weitao Fu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lulu Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lulu Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lulu++Zheng">Lulu Zheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiguo Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiguo Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiguo++Liu">Zhiguo Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Guang Liang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guang Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</div><div class="loa-info-affiliations-info">School of Chemical Engineering, Nanjing University of Science and Technology, Nanjing, Jiangsu 210094, China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone/fax: +86 577 86699396. E-mail: <a href="/cdn-cgi/l/email-protection#21565b4c424d48404f464654404f46611017120f424e4c"><span class="__cf_email__" data-cfemail="e7909d8a848b8e8689808092868980a7d6d1d4c984888a">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guang++Liang">Guang Liang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8278-849X" title="Orcid link">http://orcid.org/0000-0002-8278-849X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01310&amp;href=/doi/10.1021%2Facs.jmedchem.7b01310" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4290–4300</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 14, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 September 2017</li><li><span class="item_label"><b>Published</b> online</span>14 November 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01310</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4290%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLingfeng%2BChen%252C%2BWeitao%2BFu%252C%2BLulu%2BZheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D10%26contentID%3Dacs.jmedchem.7b01310%26title%3DRecent%2BProgress%2Bof%2BSmall-Molecule%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BInhibitors%2Bagainst%2BC797S%2BResistance%2Bin%2BNon-Small-Cell%2BLung%2BCancer%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4300%26publicationDate%3DMay%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01310"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7280</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">45</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01310" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Lingfeng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Weitao&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;Lulu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Zhiguo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Guang&quot;,&quot;last_name&quot;:&quot;Liang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;4290-4300&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01310&quot;},&quot;abstract&quot;:&quot;The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule inhibitors, especially osimertinib, are at the forefront clinically for treatment of patients with NSCLC. However, a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 (C797S) mutation in the EGFR kinase domain. This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs. In this Miniperspective, we present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance. Specifically, we analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations. Lastly, we provide some perspectives on new challenges and future directions in this field.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01310&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01310" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01310&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01310" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01310&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01310" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01310&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01310&amp;href=/doi/10.1021/acs.jmedchem.7b01310" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01310" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01310" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26pmid%3D29136465%26genre%3Darticle%26aulast%3DChen%26date%3D2018%26atitle%3DRecent%2BProgress%2Bof%2BSmall-Molecule%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BInhibitors%2Bagainst%2BC797S%2BResistance%2Bin%2BNon-Small-Cell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/jmcmar.2018.61.issue-10/20180524/jmcmar.2018.61.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule inhibitors, especially osimertinib, are at the forefront clinically for treatment of patients with NSCLC. However, a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 (C797S) mutation in the EGFR kinase domain. This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs. In this Miniperspective, we present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance. Specifically, we analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations. Lastly, we provide some perspectives on new challenges and future directions in this field.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer accounts for more than one-quarter of cancer-related deaths worldwide, and the 5-year relative survival is currently less than 20%.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Non-small-cell lung cancer (NSCLC) is the most common subtype of lung cancer, which accounts for about 80–85%.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> A member of the ErbB family, the epidermal growth factor receptor (EGFR) is fundamentally important in cell proliferation, survival, migration, adhesion, and differentiation and is one of the most valuable drug targets for the treatment of NSCLC.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> At least one activating mutation in the tumor genome of patients, such as single amino acid replacement in exon 21 (L858R) or deletion in exon 19 (delE746-A750, del19), is required for a discernible response to treatment with EGFR tyrosine kinase inhibitors (TKIs).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In 2009 and 2013, FDA approved first-generation TKIs gefitinib and erlotinib for EGFR activating mutation-positive NSCLC patients, which resulted in massive and rapid tumor volume shrinkage.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, patients typically develop secondary T790M gatekeeper drug resistance after about 12 months of treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Also, the clinical application of second-generation irreversible inhibitor afatinib (BIBW2992)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> is limited due to its poor therapeutic window.</div><div class="NLM_p">Currently, third-generation EGFR TKIs are being developed for effective management of T790M-associated resistance while sparing wild-type EGFR (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). WZ4002<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> is the first reported third-generation compound, with 30–100 times more potency against EGFR T790M than to wild-type EGFR. In a phase II trial of <b>1</b> (rociletinib, also known as CO-1686),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> structurally similar to WZ4002, treated T790M-positive patients sustain a response rate of 59% (27 out of 46 patients) and high disease control rate (93%) but T790M-negative patients show lower respective rates of 29% and 59%. However, Clovis has halted the further development of rociletinib after the FDA rejected the request for accelerated approval and required more randomized data.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Clinical studies also indicated that rociletinib may cause hyperglycemia by inhibition of off-targets including insulin-like growth factor receptor and insulin receptor kinases.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a><b>2</b> (osimertinib, also known as AZD9291),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> with a distinct monoanilinopyrimidine scaffold, became the first globally approved TKI for EGFR T790M-positive NSCLC patients in 2015 following the progress of previous generations of TKI. Moreover, <b>3</b> (olmutinib, also known as HM61713),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> with a thieno[3,2-<i>d</i>]pyrimidin core, is approved by the Korean Ministry of Food and Drug Safety in 2016 for treatment of NSCLC patients with T790M mutation. Other third-generation EGFR TKIs including <b>4</b> (nazartinib, EGF816, NCT02108964),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a><b>5</b> (naquotinib, ASP8273, NCT02500927),<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><b>6</b> (avitinib, AC0010, NCT02274337),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and <b>7</b> (PF06747775, NCT02349633)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> are currently in early clinical trials.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Third-generation EGFR-TKIs and their clinical trials status. The image of EGFR T790M/C797S kinase domain was generated by Pymol (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Acquired Resistance to Third-Generation EGFR Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the therapeutic successes of third-generation EGFR TKIs, acquired resistance remains a significant clinical issue in patient’s quality of life. Investigations of <b>1</b>–<b>3</b> from clinical trials and in vitro experimental models indicate multiple mechanisms of resistance, in part attributed to the known heterogeneity of the NSCLC cell population. <a href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf" class="ext-link">Table S1 in Supporting Information</a> summarizes the most recognized resistance mechanisms of third-generation EGFR TKIs: (1) EGFR-dependent ligand/receptor amplification and tertiary amino acid missense mutations in the ATP site of the kinase domain, e.g., C797S,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> L718Q,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> G796D,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> L792F/H,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> L798I,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> L692V,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> EGFR amplification;<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (2) EGFR-independent (bypass) pathway, attributed to alterations of other signaling molecules, such as MET,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> FGFR,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> IGF1R<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> signaling; and (3) phenotype transformation, e.g., epithelial–mesenchymal transition (EMT) and transformation to small cell lung cancer (SCLC).<a onclick="showRef(event, 'ref9 ref30'); return false;" href="javascript:void(0);" class="ref ref9 ref30">(9,30)</a> Among all these possible mechanisms, tertiary C797S mutation in the EGFR kinase domain is the most difficult one to deal with and accounts for more than 20% incidence rate from clinical data.<a onclick="showRef(event, 'ref14 ref31'); return false;" href="javascript:void(0);" class="ref ref14 ref31">(14,31)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Current Understanding of EGFR C797S-Mediated Resistance</h3><div class="NLM_p last">Third-generation EGFR TKIs have a Michael receptor warhead component, which can react with active thiols of Cys797 within the EGFR ATP binding domain, thereby forming a covalent bond. However, mutant EGFR with C797S cannot form a covalent bond with third-generation EGFR TKIs, since serine fails to form a covalent bond in a Michael addition under physiological conditions, thus providing a key mechanism of resistance. In 2014, Byrd et al. reported a cysteine-to-serine mutation in Bruton’s tyrosine kinase (BTK) which confers resistance to the tyrosine kinase inhibitor, ibrutinib, in chronic lymphocytic leukemia (CLL).<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> The finding indicates that the resistance from BTK C481S is mechanistically consistent with that from the EGFR C797S mutation. Thress et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> performed droplet digital PCR (ddPCR) on cell-free plasma DNA (cfDNA) collected from 15 osimertinib-treated patients in the phase I/II AURA trial (NCT01802632). The findings indicate that the acquired C797S mutation occurs in a marked proportion of osimertinib-resistant patients (6 out of 15 cases, 40%). In another case report, a female patient with stage IV lung adenocarcinoma, already harboring EGFR 19 exon deletion and T790M double mutations, develops a third mutation (C797S) following treatment with 9 months with <b>2</b>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Similalry, Ahn et al.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> reported a case of C797S mutation as resistance mechanism of <b>3</b>. In a phase I/II trial, a 57-year-old female with EGFR 19 exon deletion develops a T790M mutation after gefitinib treatment and acquires a C797S mutation after 17 months of treatment with <b>3</b>. Recent clinical study using <b>2</b> as first-line treatment of EGFR mutant positive advanced NSCLC (NCT01802632) demonstrated a robust ORR and prolonged PFS in patients. But 2 of 9 resistant patients were detected having EGFR C797S mutation.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Occurrence of Multiple Mechanisms of Resistance within a Cancer</h3><div class="NLM_p last">In addition to the acquired C797S mutation, the EGFR-independent pathway also leads to resistance to third-generation TKIs. A study based on tissue biopsies of post-treatment with <b>2</b> indicated that MET amplification is one of the acquired mechanisms of resistance.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The strategy of combined EGFR-TKIs with inhibition of signaling by the EGFR-independent pathway appears to be effective in delaying or overcoming the acquired resistance, driving a growing interest in combined therapy to improve patient outcomes. Although most strategies relied on combining a blocker of EGFR in combination with an inhibitor of the EGFR-independent pathway, Moores and co-workers recently developed an antibody with ability to inhibit primary/acquired EGFR mutations as well as the MET pathway.<a onclick="showRef(event, 'ref15 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref15 ref37 ref38">(15,37,38)</a><a href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf" class="ext-link">Table S2</a> lists the current clinical trials launched to evaluate combined therapies of third-generation EGFR-TKIs with inhibitors of EGFR-independent pathway. For <b>2</b>, more than 13 early phase clinical trials are currently ongoing, including targeting TORC1/2 (NCT02503722), Bcl2 (NCT02520778), VEGFR2 (NCT02789345), MEK (NCT02143466), MET (NCT02143466), Abl1/Src (NCT02954523), JAK-1 (NCT02917993), FGFR (NCT02664935), and AKT (NCT02664935). The therapeutic results are highly anticipated in the near future.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  Emerging EGFR-TKIs To Combat C797S Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">EGFR C797S point mutation is the most common mechanism of acquired resistance to third-generation EGFR-TKIs. Niederst et al.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> reported that the allelic context of the acquired C797S mutation after treatment with third-generation EGFR-TKIs may impact subsequent clinical treatment decisions. For example, with the cases of C797S and T790M mutations in trans, cancer cells are resistant to third-generation TKIs but sensitive to a combination treatment of first- and third-generation TKIs. And if the mutations are in cis, the current EGFR-TKIs are ineffective in suppressing tumor progression.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Wang et al.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> was the first to report the clinical efficacy of combination of first- and third-generation EGFR-TKIs targeting EGFR T790M and C797S in trans. However, after 3 months of PFS, the patient experienced exacerbation with the emergence of EGFR C797S located in cis with T790M. Thus, new agents to overcome the L858R/T790M/C797S or del19/T790M/C797S mutatations are critically important. Emerging structural studies of EGFR mutants are providing invaluable insights of binding modes and pharmacological significance. Recently, Kong and co-workers<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> generated complex crystal structures of EGFR mutants T790M/C797S (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>) and observed that the C797S mutation increases the local hydrophilicity around residue 797, without affecting the structure and function of the kinase domain. Therefore, in addition to the importance of covalent binding with Cys797, construction of small molecule inhibitors that enhance the binding affinity to other regions of the EGFR kinase domain and identification of new allosteric sites are key elements in the development of fourth-generation EGFR inhibitors.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  EAI045</h3><div class="NLM_p">To search for an allosteric EGFR inhibitor, Jia et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> screened a 2.5 million compound library, identifying <b>8</b> (EAI001, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><i>N-</i>(4,5-dihydrothiazol-2-yl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide. It has selectivity against the L858R/T790M mutant but spares the wild-type form. High concentration ATP screening further confirms that <b>8</b> is a potentially non-ATP-competitive (allosteric) inhibitor.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure and binding mode of the allosteric inhibitors. (A) Chemical structure of <b>8</b>. (B) Overall view of <b>8</b> bound to EGFR T790M/V948R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>). <b>8</b> is shown in green, kinase protein in pink, αC-helix in slate. Hydrogen bond between <b>8</b> and DFG is shown as red dotted line. (C) Chemical structure of <b>9</b>. (D) Overview of the classic EGFR ATP binding pocket (green) and the created allosteric site (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of <b>8</b> with the EGFR T790M mutant kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>) shows the inhibitor bound within the allosteric pocket near the classic ATP binding pocket, which is partially formed by the outward displacement of the αC-helix structure (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><b>8</b> binds as a “three-bladed propeller” or “Y shaped” configuration.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, the aminothiazole fragment stretches to the T790M gatekeeper residue, accounting for the selectivity for the T790M mutant. The phenyl group inserts into a hydrophobic gap at the back of the ATP binding pocket, thereby interacting with the Leu-777 and Phe-856 residues, while the third region, the oxoisoindolinyl moiety, extends along the αC-helix toward the solvent exposed area. In addition, the amido group of <b>8</b> forms a hydrogen bond with Asp-855 in the Asp-Phe-Gly (DFG) motif.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p last">Further medicinal chemistry optimization of its phenyl group yielded a more potent inhibitor <b>9</b> (EAI045, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C, EGFR L858R/T790M IC<sub>50</sub> = 3 nM) and maintains 1000-fold selectivity against wild-type EGFR. However, the binding site of <b>9</b> was created by the movement of the αC-helix when EGFR kinase was in the inactive conformation. And two subunits of the ErbB asymmetric dimer make the allosteric binding site inaccessible; thus the efficacy of single <b>9</b> agent is limited. With the combination use of dimer-disrupting antibody cetuximab, each EGFR kinase domain can be successfully accessed by <b>9</b>. Compound <b>9</b> synergizes with cetuximab to promote tumor regression in L858R/T790M EGFR and L858R/T790M/C797S EGFR mutants in mouse models.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Because of its distinct binding site, the authors also speculate that combination use of ATP-site-directed inhibitors and <b>9</b> is expected to overcome the acquired resistance. Interestingly, the second-generation EGFR inhibitor neratinib not only occupies the ATP site but also extends into the allosteric pocket, occupying two of the three blades of <b>9</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Thus, we speculate that structure-based design of fourth-generation EGFR-TKIs enabling interactions with both ATP and allosteric sites will be of great value.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.2.  Brigatinib</h3><div class="NLM_p">Duong-Ly et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> recently screened 183 small-molecule compounds against 76 drug-resistant mutant kinases and reported the potential repurposing opportunities for FDA-approved kinase inhibitors. On the basis of this information, Uchibori et al.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> conducted a focused drug screening to examine their efficacy against triple mutant (del19/T790M/C797S) EGFR. Among 30 selected compounds, <b>10</b> (brigatinib) potently inhibits the proliferation of Ba/F3 cells harboring the triple mutation. Different from the inhibition mechanism of <b>9</b>, <b>10</b> acts on EGFR kinase domain by competitive inhibition of ATP binding<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p"><b>10</b> was developed as a next-generation inhibitor targeting anaplastic lymphoma kinase (ALK); thus several other ALK-TKIs with similar chemical structures to <b>10</b> were also investigated, namely, <b>11</b> (TAE684), <b>12</b> (ASP3026), <b>13</b> (AP26113 analog), <b>14</b> (ceritinib), and <b>15</b> (AZD3463) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Initial structure–activity relationship (SAR) analysis reveals functional groups important for maintaining the activity to the triple mutant EGFR. The replacement of a 4-methylpiperazine group (<b>10</b>) to a dimethylamino moiety (<b>13</b>) barely affected the inhibitory potency against del19/T790M/C797S triple mutant EGFR. However, introduction of the isopropylsulfonyl (<b>11</b>) and indole (<b>15</b>) group decreases activity against the triple mutant EGFR, suggesting that phosphine oxide group in <b>10</b> is more favored. The removal of chloride (<b>12)</b> leads to a great loss of activity, and moreover, the isopropoxy group in <b>14</b> might work as a negative factor. Overall, this area needs more systematic SAR analysis and investigation.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of inhibitors <b>10</b>–<b>15</b> and their cell growth inhibition activities against Ba/F3 cells expressing del19/T790M/C797S EGFR mutants using the CellTiter-Glo assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Studies of in silico docking indicate that the 2-aminopyrimidine core of <b>10</b> forms two classic hydrogen bonds with the backbone amide of residue Met793 and fits into the pocket without steric hindrance to C797S or T790M. The phosphine oxide moiety completely occupies the triphosphate-binding region in the ATP-binding pocket, providing electrostatic or van der Waals interactions. Phosphine oxide-linked phenyl and piperidin groups contribute less to the affinity than other components and allow for further structural modification. In a nude mice model implanted with EGFR del19/C797S/T790M-expressing PC9 cells, treatment with <b>10</b> at 75 mg kg<sup>–1</sup> day<sup>–1</sup> showed significant inhibition of the tumor growth, compared with the <b>2</b> (50 mg kg<sup>–1</sup> day<sup>–1</sup>) treated group. In addition, administration of <b>10</b> (75 mg/kg) combined with cetuximab (1 mg per mouse) three times a week synergistically suppressed the growth of EGFR del19/C797S/T790M-expressing cells in vivo.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This in vivo evidence demonstrated the potential of <b>10</b>. A phase 2 trial is ongoing to assess the preliminary antitumor activity of <b>10</b>, both in non-small-cell lung cancer (NSCLC) with ALK gene rearrangement or mutated EGFR (NCT01449461). However, <b>10</b> is an inhibitor targeting multiple kinases, including ALK, ROS1, FLT3, and EGFR. We believe that <b>10</b> might be an appropriate lead compound for the design of next-generation EGFR inhibitors. It would be crucial to develop more specific and potent inhibitors against EGFR triple mutants by medicinal chemistry methods.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.3.  4-Aminopyrazolopyrimidines</h3><div class="NLM_p">4-Aminopyrazolopyrimidine is one of the important kinase hinge range binding pharmacophores.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The most extensively studied 4-aminopyrazolopyrimidine molecule, ibrutinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), has excellent antitumor activities in EGFR mutant NSCLC and is now in phase I/II clinical trial for NSCLC (NCT02321540).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> On the basis of ibrutinib’s scaffold, Wang et al.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> discovered compound <b>17</b> with high potency against EGFR drug-resistant mutant L858R/T790M (IC<sub>50</sub> < 0.3 nM). However, <b>17</b> only has moderate antiproliferative activity in EGFR-BaF3 isogenic cell lines harboring C797S mutation (IC<sub>50</sub> > 2 μM).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of inhibitors <b>16</b>–<b>20</b> and their activities against EGFR kinase and its mutants. The enzymes activities of <b>18</b>–<b>20</b> against EGFR kinase and its mutants were performed using HTRF KinEASE-TK assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Engel et al.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> reported three 4-aminopyrazolopyrimidines and evaluated their efficacy for EGFR drug-resistant mutants, including recently discovered C797S tertiary mutation. Compounds <b>18</b>–<b>20</b> display excellent inhibition in H1975 cells (GI<sub>50</sub> values of 0.21 μM, 0.49 μM, and 0.14 μM, respectively). Notably, compound <b>20</b>, decorated with 2-napthalene, has promising activity against the L858R/T790M/C797S mutant kinase with IC<sub>50</sub> of 88 nM. However, <b>20</b> is structurally similar to <b>17</b>, which has only moderate activity. Clearly, additional investigation of compound <b>20</b> in C797S mutant harboring cell lines as well as in vivo is needed for further confirmation.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.4.  Trisubstituted Imidazoles</h3><div class="NLM_p">Through screening for kinase selectivity of a p38α MAP kinase inhibitor <b>21</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), Selig et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> found EGFR as one of its off-targets. Since <b>21</b> is a promising lead compound with low toxicity, Laufer and his colleagues<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> employed target hopping strategies to discover novel EGFR inhibitors against EGFR L858R/T790M and clinically challenging L858R/T790M/C797S mutants. By transfer of the aromatic phenol group of <b>21</b> to aliphatic alcohol chains, active compounds <b>22</b> (2-hydroxypropyl) and <b>23</b> (4-hydroxypropyl) are produced that inhibit the triple mutant with IC<sub>50</sub> values of 7.6 nM (<b>22</b>) and 8.4 nM (<b>23</b>), respectively. In comparison, <b>2</b> exhibits about 35-fold weaker potency than <b>22</b> and <b>23</b> with an IC<sub>50</sub> value of 278 nM.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Molecular docking studies suggest that the aliphatic alcohol chains form beneficial hydrogen bonds to Asn-842, thereby increasing inhibitory activity.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of inhibitors <b>21</b>–<b>27</b> and their activities against EGFR kinase and its mutants. The enzymes activities of <b>21</b>–<b>27</b> were tested in a radiolabeled 33P(ATP) kinase assay or HTRF KinEASE-TK assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the same time, the Laufer group<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> screened about 2000 compounds that are structurally related to <b>21</b> against EGFR kinase and discovered compound <b>24</b> as a promising lead structure for further modification. SAR examination has led to development of active compounds consisting of multiple hydrophobic and polar interactions with several regions within the EGFR ATP binding domain. Compounds <b>25</b>–<b>27</b><a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> with or without the Michael receptor reversibly inhibit the EGFR L858R/T790M/C797S triple mutant with low nanomolar IC<sub>50</sub> values. Our modeling studies of <b>25</b> with EGFR T790M/C797S reveal that the aminopyridine moiety binds to the hinge region with bidentate hydrogen bonds, and the fluorophenyl group contributes to the hydrophobic interactions with surrounding residues (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). In addition, a polar contact occurs between the hydroxyl group and the Arg-841. And two hydrogen bonds are formed between the carbanyl group and the mutated Ser-797. In terms of the discovery of C797S-targeting inhibitors, compounds without a Michael receptor (e.g., <b>26</b>) may be more selective and safe since they lose the ability to covalently bind to off-target kinases. The trisubstituted imidazoles may serve as potential lead for the further development of highly potent fourth-generation EGFR inhibitors. Further optimization needs to reduce the inhibitory activity on wild-type EGFR.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibitors binding with EGFR C797S/T790M mutant: (A) chemical structure of <b>25</b> and its depicted binding mode; (B) binding mode of <b>25</b> with the EGFR C797S/T790M mutant; (C) chemical structure of <b>31</b> and its depicted binding mode; (D) binding mode of <b>31</b> with the EGFR C797S/T790M (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>) mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.5.  2-Aryl-4-aminoquinazolines</h3><div class="NLM_p">Recently, Park et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> relied on a two-track virtual screening strategy to search for EGFR del/T790M/C797S mutant selective inhibitors with low binding free energies but high binding free energies to WT EGFR. After virtual and experimental screening of a 670 000 compound chemical database, hit compound <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) possesses promising submicromolar inhibitory activity against the EGFR del/T790M/C797S mutant and 163-fold selectivity over WT EGFR. SAR examination indicates that the most potent compounds <b>29</b>, <b>30</b>, and <b>31</b> display more than 1000-fold selectivity for the triple mutant over the wild type, as well as nanomolar inhibitory activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Binding mode analysis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D) reveals the terminal phenolic moiety of <b>31</b> forming two hydrogen bonds with Met-793 and Gln-791, respectively. Moreover, the pyridin-3-yl-methylamine moiety forms two more hydrogen bonds with the hydroxy group of the mutated Ser-797. The removal of -OH group or change of the -NH to oxygen leads to loss of inhibitory activity, further confirming the strong interactions between compounds, Ser-797 and Met-793 residues.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of inhibitors <b>28</b>–<b>31</b> and their activities against EGFR kinase and its mutants using radiolabeled 33P(ATP) kinase assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">4.  Real-Time Circulating Tumor DNA as Marker for NSCLC</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Personalized medicine in cancer therapy relies on the customization of healthcare guided by molecular analyses.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In the clinical setting, tissue-based tumor sample cannot reflect the overall heterogeneity of the tumor and cannot be obtained repeatedly because of its invasive procedure. In contrast, the detection of circulating tumor DNA (ctDNA), commonly known as “liquid biopsies”, can help monitor response to therapy, identify acquired drug resistance in a timely way, and enable clinicians to repeatedly and noninvasively obtain blood samples to track the progression of cancers.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Over the past 5 years, technologies to analyze ctDNA, especially droplet digital PCR (ddPCR) and next-generation sequencing (NGS), have advanced significantly. Specifically, ddPCR can monitor the dynamic individual mutations but requires knowing the mutant allele in advance. However, NGS has strong advantages over ddPCR in discovering novel mutated variants and has becoming a key tool for precision medicine. Though the clinical utility of NGS remains to be verified in more comprehensive studies, this approach may become preferable over ddPCR during the treatment of NSCLC due to the high complexity and unpredictable of C797S mutations, including multiple DNA variants, cis versus trans, different coexisting C797S mutations, and other tertiary EGFR mutations.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The U.S. FDA recently has approved the use of liquid biopsies for detection of EGFR mutations in NSCLC patients. Such methods provide a comprehensive view of specific resistance mutations during a treatment period, such as acquired EGFR gatekeeper and C797S mutations associated with EGFR-TKIs treatment.<a onclick="showRef(event, 'ref59 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref59 ref62 ref63">(59,62,63)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">5.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70461" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70461" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Treatment of NSCLC patients with the T790M mutation with third-generation EGFR-TKIs is highly promising, but drug resistance still occurs. Novel technologies that detect ctDNA are highly useful by monitoring dynamic mutations in disease progression. Among the escaped mechanisms, C797S point mutation is the most frequent mechanism of acquired resistance to third-generation TKIs attributed to loss of the irreversible binding site of third-generation TKIs. Moreover, when C797S and T790M alleles occur in cis, there is no current therapeutic drug available to suppress disease progression. Thus, there is an urgent need to develop therapeutic agents effective against EGFR tertiary mutants. The relatively new development of next generation small molecule EGFR-TKIs with different scaffolds and binding mechanisms appears hopeful. The ongoing combination trials with third-generation TKIs may change the treatment paradigm for EGFR mutant NSCLC in the near future (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Intratumoral heterogeneity and future treatment paradigm of patients with EGFR mutant NSCLC. Each colored ball represents a distinct clone with newly acquired resistance mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Highly potent non-ATP-competitive MEK1/2 allosteric inhibitors (cobimetinib and refametinib) have been developed and tested in numerous clinical trials over the past decade.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> The recently developed EGFR allosteric inhibitor <b>9</b>, which binds to the analogous site, showed excellent therapeutic efficacy to lung cancers driven by the triple L858R/T790M/C797S mutant when synergized with cetuximab. Through mutant targeted drug screening and structure-based de novo optimization, other novel ATP-competitive molecules with a distinct scaffold from third-generation EGFR-TKIs are identified and demonstrated excellent inhibitory activity against acquired C797S resistant mutants.</div><div class="NLM_p last">Despite these advances, several major limitations and challenges remain. (1) Allosteric inhibitor <b>9</b> is capable of inhibiting the EGFR L858R/T790M/C797S mutation but may lose its efficacy against del/T790M/C797S due to the reduced space of the allosteric pocket. The competitive inhibitor <b>10</b> tends to be less sensitive to L858R/T790M/C797S mutant than del19/T790M/C797S. Additionally, both <b>9</b> and <b>10</b> exhibit mechanistic synergy when combined with cetuximab, but the potency of single therapy is not satisfying in vivo. Thus, there remains a big challenge to develop fourth-generation TKIs with broader drug-resistant mutant selectivity and greater inhibitory capacity. (2) Several newly discovered molecules, i.e., trisubstituted imidazoles and 4-aminopyrazolopyrimidines, exhibit potent activity against the C797S mutant but have low or no selectivity against WT EGFR. With the recognized importance of EGFR T790M and C797S mutants in acquired resistance, development of TKIs with high selectivity for the mutants is critical in the next generation drug discovery. (3) Finally, more comprehensive in vivo studies of newly developed agents are needed to validate their in vitro efficacy.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01310" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01310" class="ext-link">10.1021/acs.jmedchem.7b01310</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Mechanisms of resistance and results of combination trials (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf">jm7b01310_si_001.pdf (111.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01310" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guang Liang</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Chemical Engineering, Nanjing University
of Science and Technology, Nanjing, Jiangsu 210094, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8278-849X" title="Orcid link">http://orcid.org/0000-0002-8278-849X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#abdcd1c6c8c7c2cac5ccccdecac5cceb9a9d9885c8c4c6"><span class="__cf_email__" data-cfemail="ddaaa7b0beb1b4bcb3babaa8bcb3ba9decebeef3beb2b0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lingfeng Chen</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Chemical Engineering, Nanjing University
of Science and Technology, Nanjing, Jiangsu 210094, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weitao Fu</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lulu Zheng</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiguo Liu</span> - <span class="hlFld-Affiliation affiliation">Chemical
Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Lingfeng Chen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=BIO-d162e1122-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lingfeng Chen</b> received his B.S. and M.S. degree in Pharmacy from Wenzhou Medical University in China. Now he is studying for a Ph.D. degree at Nanjing University of Science and Technology in China. The focus of his research is on structure-based drug design, lead optimization, and biological activity screening of tyrosine kinase inhibitors. During his Master’s degree study, he has designed and synthesized a number of EGFR and FGFR kinase inhibitors as potential anticancer candidates.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Weitao Fu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=BIO-d162e1127-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Weitao Fu</b> obtained his B.S. degree and M.S. degree in Pharmacy at Wenzhou Medical University in China. Now he is studying for Ph.D. degree in Pharmacy at Zhejiang University in China. His research interests lie in the area of computer-aided drug design, including molecular docking, structure-based virtual screening, and molecular dynamics simulations, with primary focus on the structure-based design of antiprostate cancer targeting androgen receptor.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Lulu Zheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=BIO-d162e1132-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Lulu Zheng</b> received her B.S. and M.S. degrees in Pharmacy from Wenzhou Medical University in China. The focus of her research is on anticancer drug screening especially against epidermal growth factor receptor and fibroblast growth factor receptor. Using kinase and cellular based assays and xenograft animal models, she has discovered several promising candidates for further exploration.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Zhiguo Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=BIO-d162e1137-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhiguo Liu</b> earned his B.S. degree in Pharmaceutical Engineering from Changchun University Of Chinese Medicine  in 2004 and then received his Ph.D. degree in Medicinal Chemistry from Chonnam National University (Gwangju, Korea) in 2011. Now, he is a Full Professor at School of Pharmaceutical Sciences of Wenzhou Medical University, China. Dr. Liu’s research interests are the design and synthesis of new chemotherapeutic drugs as well as the discovery of new bioactive natural products. He has published more than 40 peer-reviewed articles as the first or corresponding author in the fields of medicinal chemistry and organic chemistry.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Guang Liang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=BIO-d162e1142-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Guang Liang</b> earned his B.S. degree in Applied Chemistry from Beijing University of Chemical Technology in 2002 and received his Ph.D. in Biological Chemistry from Nanjing University of Science and Technology (Nanjing, China) in 2008. Now, he is a Full Professor and the Dean of School of Pharmaceutical Sciences in Wenzhou Medical University, China. His research interest is focused on design and discovery of novel anti-inflammatory and anticancer small molecules. He has published more than 100 peer-reviewed articles as the corresponding author in the fields of medicinal chemistry and biochemical pharmacology.</p></figure></div><div class="ack" id="ACK-d162e965-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (Grants 81622043, 81773579) and the Natural Science Foundation of Zhejiang Province (Grants LR16H310001, LY17B020008).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">ctDNA</td><td class="NLM_def"><p class="first last">circulating tumor DNA</p></td></tr><tr><td class="NLM_term">cfDNA</td><td class="NLM_def"><p class="first last">cell-free plasma DNA</p></td></tr><tr><td class="NLM_term">ddPCR</td><td class="NLM_def"><p class="first last">droplet digital PCR</p></td></tr><tr><td class="NLM_term">NGS</td><td class="NLM_def"><p class="first last">next-generation sequencing</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small cell lung cancer</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression free survival</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">SFK</td><td class="NLM_def"><p class="first last">Src family kinase</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homolog deleted on chromosome 10</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">JAK-1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2017</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3322%2Fcaac.21387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28055103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1c7isFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2017&doi=10.3322%2Fcaac.21387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2017</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States.  For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher.  However, sex disparities vary by cancer type.  For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women.  From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.  Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%).  Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population.  CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB4oj7vNRTIb5oR8RchjrrfW6udTcc2ebl3nHoyKqMN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7isFWgtA%253D%253D&md5=e439f3424d5a773e4ae289c392236ad6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21387%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202017%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2017%26volume%3D67%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues Pereira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuleanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maoleekoonpiroj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kooten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dediu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezjak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santabarbara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">National Cancer Institute of Canada Clinical Trials, G. Erlotinib in previously treated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=National+Cancer+Institute+of+Canada+Clinical+Trials%2C+G.+Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lgi8s9keQK0Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DNational%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%252C%2520G.%2520Erlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhYblSZGUf6tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhYblSZGUf6tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maemondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukiwa, T.</span></span> <span> </span><span class="NLM_article-title">North-East Japan Study, G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2388</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0909530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=North-East+Japan+Study%2C+G.+Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR&doi=10.1056%2FNEJMoa0909530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lh4zhFoBxP3Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DNorth-East%2520Japan%2520Study%252C%2520G.%2520Gefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388%26doi%3D10.1056%2FNEJMoa0909530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lh4zhFoBxP3Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2014.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24981256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=473-481&author=D.+R.+Camidgeauthor=W.+Paoauthor=L.+V.+Sequist&title=Acquired+resistance+to+TKIs+in+solid+tumours%3A+learning+from+lung+cancer&doi=10.1038%2Fnrclinonc.2014.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span></div><div class="casAuthors">Camidge, D. Ross; Pao, William; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of advanced mol. profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease.  However, acquired resistance, defined as progression after initial benefit, to targeted therapies inevitably occurs.  This Review explores breakthroughs in the understanding and treatment of acquired resistance in NSCLC, focusing on EGFR mutant and ALK rearrangement-pos. disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes.  Mechanisms of acquired resistance may be pharmacol. (i.e., failure of delivery of the drug to its target) or biol., resulting from evolutionary selection on molecularly diverse tumors.  A no. of clin. approaches can maintain control of the disease in the acquired resistance setting, including the use of radiation to treat isolated areas of progression and adding or switching to cytotoxic chemotherapy.  Furthermore, novel approaches that have already proven successful include the development of second-generation and third-generation inhibitors and the combination of some of these inhibitors with antibodies directed against the same target.  With our increased understanding of the spectrum of acquired resistance, major changes in how we conduct clin. research in this setting are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00ixSKYoDuLVg90H21EOLACvtfcHk0liU9rE2S-BfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL&md5=13cc2f49f7ef320ad54f7e84f5102816</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.104%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DAcquired%2520resistance%2520to%2520TKIs%2520in%2520solid%2520tumours%253A%2520learning%2520from%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D473%26epage%3D481%26doi%3D10.1038%2Fnrclinonc.2014.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liU9rE2S-BfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.,  St</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhNrCxtwnhcjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">113</span>, <span class="refDoi"> DOI: 10.3389/fonc.2017.00113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3389%2Ffonc.2017.00113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28620581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=113&author=T.+A.+Barnesauthor=G.+M.+O%E2%80%99Kaneauthor=M.+D.+Vincentauthor=N.+B.+Leighl&title=Third-generation+tyrosine+kinase+inhibitors+targeting+epidermal+growth+factor+receptor+mutations+in+non-small+cell+lung+cancer&doi=10.3389%2Ffonc.2017.00113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Barnes Tristan A; O'Kane Grainne M; Leighl Natasha B; Vincent Mark David</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer.  Eventual resistance develops with multiple mechanisms identifiable both upon repeat biopsy and in plasma circulating tumor DNA.  The T790M gatekeeper mutation is responsible for almost 60% of cases.  A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy.  Resistance mechanisms are being identified to these novel agents, and the treatment landscape of EGFR-mutant lung cancer continues to evolve.  The sequence of EGFR TKIs may change in the future and combination therapies targeting resistance appear highly promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT45i3zpRyq-4hLSh9fo81bfW6udTcc2ebIc31_EApjVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D&md5=591385d1fc87186675e46ad3621dc82b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00113%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DThird-generation%2520tyrosine%2520kinase%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D113%26doi%3D10.3389%2Ffonc.2017.00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1709</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eYPW1X3jitqgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villadolid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ersek, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirianno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Story, E. S.</span></span> <span> </span><span class="NLM_article-title">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.10.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3978%2Fj.issn.2218-6751.2015.10.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26629426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=576-583&author=J.+Villadolidauthor=J.+L.+Ersekauthor=M.+K.+Fongauthor=L.+Siriannoauthor=E.+S.+Story&title=Management+of+hyperglycemia+from+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+targeting+T790M-mediated+resistance&doi=10.3978%2Fj.issn.2218-6751.2015.10.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span></div><div class="casAuthors">Villadolid, Jeryl; Ersek, Jennifer L.; Fong, Mei Ka; Sirianno, Lindsey; Story, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-583</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to small mol. tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.  Although studies show an increased progression free survival (PFS) with use of EGFR TKIs in the first-line setting, most patients will develop resistance to therapy after the first 8-16 mo.  T790M is an acquired resistance mutation reported in 60-70% of patients who initially responded to a prior EGFR TKI.  Recently, EGFR TKIs targeting T790M have been developed to overcome resistance with pos. results in PFS and objective response rate in patients who have had disease progression on at least one TKI.  Two EGFR TKIs targeting T790M, AZD9291 and rociletinib, are new active treatment options for NSCLC but differ in adverse effect profiles.  Dose-limiting hyperglycemia has been reported with rociletinib and has required dose redn., an oral antihyperglycemic, or both, without discontinuation of therapy.  This suggests that patients may be effectively treated chronically for hyperglycemia assocd. with EGFR TKIs targeting T790M, however, guidelines for treatment of hyperglycemia in this setting have not been published.  We discuss mechanisms of hyperglycemia assocd. with TKIs and initial management of hyperglycemia, including benefits and limitations of oral antihyperglycemic options, adjustment of therapy based on grade of hyperglycemia, and recommendations for follow-up glucose monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkySpp7vMZSbVg90H21EOLACvtfcHk0ljwmXoejvB46Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D&md5=451bfbce8a87320cd07c462e36f8f6b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.10.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.10.01%26sid%3Dliteratum%253Aachs%26aulast%3DVilladolid%26aufirst%3DJ.%26aulast%3DErsek%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DM.%2BK.%26aulast%3DSirianno%26aufirst%3DL.%26aulast%3DStory%26aufirst%3DE.%2BS.%26atitle%3DManagement%2520of%2520hyperglycemia%2520from%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520targeting%2520T790M-mediated%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D576%26epage%3D583%26doi%3D10.3978%2Fj.issn.2218-6751.2015.10.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljwmXoejvB46Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+updates+on+third+generation+EGFR+inhibitors+and+emergence+of+fourth+generation+EGFR+inhibitors+to+combat+C797S+resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0lhMHz-B960WpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520updates%2520on%2520third%2520generation%2520EGFR%2520inhibitors%2520and%2520emergence%2520of%2520fourth%2520generation%2520EGFR%2520inhibitors%2520to%2520combat%2520C797S%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span> <span> </span><span class="NLM_article-title">EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-15-2581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1591-1602&author=Y.+Jiaauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=M.+J.+Niederstauthor=C.+Tompkinsauthor=N.+Timpleauthor=M.+T.+Vaillancourtauthor=A.+C.+Pferdekamperauthor=E.+L.+Lockermanauthor=C.+Liauthor=J.+Andersonauthor=C.+Costaauthor=D.+Liaoauthor=E.+Murphyauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=G.+Lelaisauthor=J.+Barretinaauthor=M.+McNeillauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=N.+Pathanauthor=J.+A.+Engelmanauthor=P.+Y.+Michellysauthor=P.+McNamaraauthor=J.+Harrisauthor=S.+Benderauthor=S.+Kasibhatla&title=EGF816+exerts+anticancer+effects+in+non-small+cell+lung+cancer+by+irreversibly+and+selectively+targeting+primary+and+acquired+activating+mutations+in+the+EGF+receptor&doi=10.1158%2F0008-5472.CAN-15-2581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2581%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DVaillancourt%26aufirst%3DM.%2BT.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKasibhatla%26aufirst%3DS.%26atitle%3DEGF816%2520exerts%2520anticancer%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520by%2520irreversibly%2520and%2520selectively%2520targeting%2520primary%2520and%2520acquired%2520activating%2520mutations%2520in%2520the%2520EGF%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D1591%26epage%3D1602%26doi%3D10.1158%2F0008-5472.CAN-15-2581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27071706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-generation+inhibitors+targeting+EGFR+T790M+mutation+in+advanced+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Cang, Shundong; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC).  However, EGFR T790M mutation leads to resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development.  These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  Osimertinib and rociletinib have shown clin. efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs.  Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-pos. NSCLC.  HM61713, ASP8237, EGF816, and PF-06747775 are still in early clin. development.  This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0o_C9ADDlbVg90H21EOLACvtfcHk0ljWgOevOQ-nzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D&md5=71185a0816b49a8e578c8563e02e2fa0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-generation%2520inhibitors%2520targeting%2520EGFR%2520T790M%2520mutation%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance</span>. <i>Chin. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1186/s40880-015-0029-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1186%2Fs40880-015-0029-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26152224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=285-287&author=X.+Xu&title=Parallel+phase+1+clinical+trials+in+the+US+and+in+China%3A+accelerating+the+test+of+avitinib+in+lung+cancer+as+a+novel+inhibitor+selectively+targeting+mutated+EGFR+and+overcoming+T790M-induced+resistance&doi=10.1186%2Fs40880-015-0029-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance</span></div><div class="casAuthors">Xu, Xiao</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">285-287</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clin. trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel.  In the preclin. studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance.  Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clin. trials, and will provide a precision targeted therapy for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryk1A36-5V-7Vg90H21EOLACvtfcHk0ljWgOevOQ-nzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVGhtw%253D%253D&md5=88ed913733876b7b35f18cc54f19ae73</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs40880-015-0029-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-015-0029-3%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DParallel%2520phase%25201%2520clinical%2520trials%2520in%2520the%2520US%2520and%2520in%2520China%253A%2520accelerating%2520the%2520test%2520of%2520avitinib%2520in%2520lung%2520cancer%2520as%2520a%2520novel%2520inhibitor%2520selectively%2520targeting%2520mutated%2520EGFR%2520and%2520overcoming%2520T790M-induced%2520resistance%26jtitle%3DChin.%2520J.%2520Cancer%26date%3D2015%26volume%3D34%26spage%3D285%26epage%3D287%26doi%3D10.1186%2Fs40880-015-0029-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3002</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3002-3019&author=S.+Plankenauthor=D.+C.+Behennaauthor=S.+K.+Nairauthor=T.+O.+Johnsonauthor=A.+Nagataauthor=C.+Almadenauthor=S.+Baileyauthor=T.+E.+Ballardauthor=L.+Bernierauthor=H.+Chengauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=J.+G.+Dealauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+Hemkensauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=J.+Matthewsauthor=B.+W.+Murrayauthor=S.+Niessenauthor=S.+T.+Orrauthor=M.+Pairishauthor=N.+W.+Sachauthor=H.+Shenauthor=M.+Shiauthor=J.+Solowiejauthor=K.+Tranauthor=E.+Tsengauthor=P.+Viciniauthor=Y.+Wangauthor=S.+L.+Weinrichauthor=R.+Zhouauthor=M.+Zientekauthor=L.+Liuauthor=Y.+Luoauthor=S.+Xinauthor=C.+Zhangauthor=J.+Lafontaine&title=Discovery+of+N-%28%283R%2C4R%29-4-Fluoro-1-%286-%28%283-methoxy-1-methyl-1H-pyrazol-4-yl%29amino%29-9-methyl-9H-+purin-2-yl%29pyrrolidine-3-yl%29acrylamide+%28PF-06747775%29+through+structure-based+drug+design%3A+a+high+affinity+irreversible+inhibitor+targeting+oncogenic+EGFR+mutants+with+selectivity+over+wild-type+EGFR&doi=10.1021%2Facs.jmedchem.6b01894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR</span></div><div class="casAuthors">Planken, Simon; Behenna, Douglas C.; Nair, Sajiv K.; Johnson, Theodore O.; Nagata, Asako; Almaden, Chau; Bailey, Simon; Ballard, T. Eric; Bernier, Louise; Cheng, Hengmiao; Cho-Schultz, Sujin; Dalvie, Deepak; Deal, Judith G.; Dinh, Dac M.; Edwards, Martin P.; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle; Kania, Robert S.; Kath, John C.; Matthews, Jean; Murray, Brion W.; Niessen, Sherry; Orr, Suvi T. M.; Pairish, Mason; Sach, Neal W.; Shen, Hong; Shi, Manli; Solowiej, James; Tran, Khanh; Tseng, Elaine; Vicini, Paolo; Wang, Yuli; Weinrich, Scott L.; Zhou, Ru; Zientek, Michael; Liu, Longqing; Luo, Yiqin; Xin, Shuibo; Zhang, Chengyi; Lafontaine, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3002-3019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC).  Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective.  Secondary oncogenic EGFR mutations account for approx. 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective.  The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.  Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clin. candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties.  Compd. 21 is currently being evaluated in phase-I clin. trials of mutant EGFR driven NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1yLRt7MBSrbVg90H21EOLACvtfcHk0lgMealURnhrNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrw%253D&md5=14a6700ed770621bdbd84f7931276f0e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DBernier%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLafontaine%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%2528%25283R%252C4R%2529-4-Fluoro-1-%25286-%2528%25283-methoxy-1-methyl-1H-pyrazol-4-yl%2529amino%2529-9-methyl-9H-%2520purin-2-yl%2529pyrrolidine-3-yl%2529acrylamide%2520%2528PF-06747775%2529%2520through%2520structure-based%2520drug%2520design%253A%2520a%2520high%2520affinity%2520irreversible%2520inhibitor%2520targeting%2520oncogenic%2520EGFR%2520mutants%2520with%2520selectivity%2520over%2520wild-type%2520EGFR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3002%26epage%3D3019%26doi%3D10.1021%2Facs.jmedchem.6b01894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgfZYLJHvHvpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumour+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0lgfZYLJHvHvpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumour%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-123&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De121%26epage%3D123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2eY2wPBTQINEf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e65</span>– <span class="NLM_lpage">e68</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2016.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28093244" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e65-e68&author=K.+Chenauthor=F.+Zhouauthor=W.+Shenauthor=T.+Jiangauthor=X.+Wuauthor=X.+Tongauthor=Y.+W.+Shaoauthor=S.+Qinauthor=C.+Zhou&title=Novel+mutations+on+EGFR+Leu792+potentially+correlate+to+acquired+resistance+to+osimertinib+in+advanced+NSCLC&doi=10.1016%2Fj.jtho.2016.12.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DNovel%2520mutations%2520on%2520EGFR%2520Leu792%2520potentially%2520correlate%2520to%2520acquired%2520resistance%2520to%2520osimertinib%2520in%2520advanced%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3De65%26epage%3De68%26doi%3D10.1016%2Fj.jtho.2016.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2eYQqji2V5_l57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knebel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, L. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, A. A.</span></span> <span> </span><span class="NLM_article-title">Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2017.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=238-241&author=F.+H.+Knebelauthor=F.+Bettoniauthor=A.+K.+Shimadaauthor=M.+Cruzauthor=J.+V.+Alessiauthor=M.+V.+Negraoauthor=L.+F.+L.+Reisauthor=A.+Katzauthor=A.+A.+Camargo&title=Sequential+liquid+biopsies+reveal+dynamic+alterations+of+EGFR+driver+mutations+and+indicate+EGFR+amplification+as+a+new+mechanism+of+resistance+to+osimertinib+in+NSCLC&doi=10.1016%2Fj.lungcan.2017.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DKnebel%26aufirst%3DF.%2BH.%26aulast%3DBettoni%26aufirst%3DF.%26aulast%3DShimada%26aufirst%3DA.%2BK.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DAlessi%26aufirst%3DJ.%2BV.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DReis%26aufirst%3DL.%2BF.%2BL.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DCamargo%26aufirst%3DA.%2BA.%26atitle%3DSequential%2520liquid%2520biopsies%2520reveal%2520dynamic%2520alterations%2520of%2520EGFR%2520driver%2520mutations%2520and%2520indicate%2520EGFR%2520amplification%2520as%2520a%2520new%2520mechanism%2520of%2520resistance%2520to%2520osimertinib%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D238%26epage%3D241%26doi%3D10.1016%2Fj.lungcan.2017.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2016.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27393507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=59-61&author=S.+H.+Ouauthor=N.+Agarwalauthor=S.+M.+Ali&title=High+MET+amplification+level+as+a+resistance+mechanism+to+osimertinib+%28AZD9291%29+in+a+patient+that+symptomatically+responded+to+crizotinib+treatment+post-osimertinib+progression&doi=10.1016%2Fj.lungcan.2016.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Agarwal Nikita; Ali Siraj M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Third-generation EGFR TKI has been approved in the US and EU for the treatment of EGFR mutant T790M+ NSCLC patients that are resistant to first- or second generation EGFR TKIs.  Here we report a patient who developed resistance to osimertinib after a confirmed partial response for 9 months.  Pre-osimertinib and post-osimertinib tumor biopsy revealed the emergence of high level of MET amplification (30 copies) post osimertinib treatment.  Patient was treated with single agent crizotinib, a known MET inhibitor, with transient symptomatic benefit.  MET amplification is one potential resistance mechanism to osimertinib and combination of osimertinib and a MET inhibitor should be investigated post-osimertinib progression in EGFR mutant T790M+ NSCLC patients whose harbored acquired MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtshWfpMXQLRstfW6udTcc2eYNuV2OuzcZi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D&md5=2cd5da962531483cb3092367da127c64</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DHigh%2520MET%2520amplification%2520level%2520as%2520a%2520resistance%2520mechanism%2520to%2520osimertinib%2520%2528AZD9291%2529%2520in%2520a%2520patient%2520that%2520symptomatically%2520responded%2520to%2520crizotinib%2520treatment%2520post-osimertinib%2520progression%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D59%26epage%3D61%26doi%3D10.1016%2Fj.lungcan.2016.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andreauthor=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2eYNuV2OuzcZi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1097%2FJTO.0000000000000688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26473643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1736-1744&author=T.+M.+Kimauthor=A.+Songauthor=D.+W.+Kimauthor=S.+Kimauthor=Y.+O.+Ahnauthor=B.+Keamauthor=Y.+K.+Jeonauthor=S.+H.+Leeauthor=D.+H.+Chungauthor=D.+S.+Heo&title=Mechanisms+of+acquired+resistance+to+AZD9291%3A+a+mutation-selective%2C+irreversible+EGFR+inhibitor&doi=10.1097%2FJTO.0000000000000688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor</span></div><div class="casAuthors">Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1736-1744</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs.  However, acquired resistance to AZD9291 is inevitable.  In this study, we identified the mechanisms of acquired resistance to AZD9291 in EGFR-mutant NSCLC.  Methods: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632).  Paired tumor samples before and after treatment were obtained to evaluate EGFR modifications, alternative pathway activation, and histol. transformation.  Genetic alterations were analyzed using Sanger sequencing, fluorescence in situ hybridization, real-time polymerase chain reaction, and targeted exome sequencing.  Results: All four patients achieved a partial response (median duration of response, 9 mo [range, 9-11 mo]) and subsequently showed resistance to AZD9291.  EGFR-mutant clones depopulated AZD9291-resistant tumors to below 1% (baseline, 14%-36%) in three patients with progression: one with the loss of EGFR-double mutant clones and two accompanied by transformation to small-cell carcinoma and focal fibroblast growth factor receptor 1 (FGFR1) amplification, resp.  EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291.  Conclusion: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histol. transformation and EGFR ligand-dependent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KLOZPHlkELVg90H21EOLACvtfcHk0lg7HWF9bM1dfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE&md5=304e993133713a74dc817f3e05c7e9db</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000688%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DY.%2BO.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%253A%2520a%2520mutation-selective%252C%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D1736%26epage%3D1744%26doi%3D10.1097%2FJTO.0000000000000688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">22005</span>– <span class="NLM_lpage">22015</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.8013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=22005-22015&author=J.+H.+Parkauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=J.+E.+Leeauthor=K.+J.+Sungauthor=S.+Parkauthor=W.+S.+Kimauthor=J.+S.+Songauthor=C.+M.+Choiauthor=Y.+H.+Sungauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Activation+of+the+IGF1R+pathway+potentially+mediates+acquired+resistance+to+mutant-selective+3rd-generation+EGF+receptor+tyrosine+kinase+inhibitors+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.8013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSung%26aufirst%3DK.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DSung%26aufirst%3DY.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DActivation%2520of%2520the%2520IGF1R%2520pathway%2520potentially%2520mediates%2520acquired%2520resistance%2520to%2520mutant-selective%25203rd-generation%2520EGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D22005%26epage%3D22015%26doi%3D10.18632%2Foncotarget.8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span> <span> </span><span class="NLM_article-title">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">18609</span>– <span class="NLM_lpage">18614</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.14506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=18609-18614&author=L.+Liauthor=H.+Wangauthor=C.+Liauthor=Z.+Wangauthor=P.+Zhangauthor=X.+Yan&title=Transformation+to+small-cell+carcinoma+as+an+acquired+resistance+mechanism+to+AZD9291%3A+a+case+report&doi=10.18632%2Foncotarget.14506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14506%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DX.%26atitle%3DTransformation%2520to%2520small-cell%2520carcinoma%2520as%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520AZD9291%253A%2520a%2520case%2520report%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D18609%26epage%3D18614%26doi%3D10.18632%2Foncotarget.14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.tips.2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=887-903&author=E.+E.+Keauthor=Y.+L.+Wu&title=EGFR+as+a+pharmacological+target+in+EGFR-mutant+non-small-cell+lung+cancer%3A+where+do+we+stand+now%3F&doi=10.1016%2Fj.tips.2016.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DE.%2BE.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DEGFR%2520as%2520a%2520pharmacological%2520target%2520in%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%253A%2520where%2520do%2520we%2520stand%2520now%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D887%26epage%3D903%26doi%3D10.1016%2Fj.tips.2016.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa1400029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24869598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2286-2294&author=J.+A.+Woyachauthor=R.+R.+Furmanauthor=T.+M.+Liuauthor=H.+G.+Ozerauthor=M.+Zapatkaauthor=A.+S.+Ruppertauthor=L.+Xueauthor=D.+H.+Liauthor=S.+M.+Steggerdaauthor=M.+Verseleauthor=S.+S.+Daveauthor=J.+Zhangauthor=A.+S.+Yilmazauthor=S.+M.+Jaglowskiauthor=K.+A.+Blumauthor=A.+Lozanskiauthor=G.+Lozanskiauthor=D.+F.+Jamesauthor=J.+C.+Barrientosauthor=P.+Lichterauthor=S.+Stilgenbauerauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=A.+J.+Johnsonauthor=J.+C.+Byrd&title=Resistance+mechanisms+for+the+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+ibrutinib&doi=10.1056%2FNEJMoa1400029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib</span></div><div class="casAuthors">Woyach, Jennifer A.; Furman, Richard R.; Liu, Ta-Ming; Ozer, Hatice Gulcin; Zapatka, Marc; Ruppert, Amy S.; Xue, Ling; Li, Daniel Hsieh-Hsin; Steggerda, Susanne M.; Versele, Matthias; Dave, Sandeep S.; Zhang, Jenny; Yilmaz, Ayse Selen; Jaglowski, Samantha M.; Blum, Kristie A.; Lozanski, Arletta; Lozanski, Gerard; James, Danelle F.; Barrientos, Jacqueline C.; Lichter, Peter; Stilgenbauer, Stephan; Buggy, Joseph J.; Chang, Betty Y.; Johnson, Amy J.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2286-2294, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).  Resistance to irreversible kinase inhibitors and resistance assocd. with BTK inhibition have not been characterized.  Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important.  We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance.  Methods: We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy.  We then performed functional anal. of identified mutations.  In addn., we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis.  Results: We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients.  Functional anal. showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.  The R665W and L845F mutations in PLCγ2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity.  These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib.  Conclusions: Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs.  This finding, combined with two addnl. mutations in PLCγ2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktSKmZODIjLVg90H21EOLACvtfcHk0lhimTWN-Y3SHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ&md5=9eaf9f3ed7518c264b413ef4fe826985</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400029%26sid%3Dliteratum%253Aachs%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DT.%2BM.%26aulast%3DOzer%26aufirst%3DH.%2BG.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%2BH.%26aulast%3DSteggerda%26aufirst%3DS.%2BM.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DDave%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYilmaz%26aufirst%3DA.%2BS.%26aulast%3DJaglowski%26aufirst%3DS.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DLozanski%26aufirst%3DA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DResistance%2520mechanisms%2520for%2520the%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520ibrutinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2286%26epage%3D2294%26doi%3D10.1056%2FNEJMoa1400029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. L.</span></span> <span> </span><span class="NLM_article-title">Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fleu.2014.263" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=895-900&author=S.+Chengauthor=A.+Guoauthor=P.+Luauthor=J.+Maauthor=M.+Colemanauthor=Y.+L.+Wang&title=Functional+characterization+of+BTK%28C481S%29+mutation+that+confers+ibrutinib+resistance%3A+exploration+of+alternative+kinase+inhibitors&doi=10.1038%2Fleu.2014.263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.263%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%2BL.%26atitle%3DFunctional%2520characterization%2520of%2520BTK%2528C481S%2529%2520mutation%2520that%2520confers%2520ibrutinib%2520resistance%253A%2520exploration%2520of%2520alternative%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D895%26epage%3D900%26doi%3D10.1038%2Fleu.2014.263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+resistance+of+EGFR-mutant+lung+cancer+to+a+T790M-specific+EGFR+inhibitor%3A+Emergence+of+a+third+mutation+%28C797S%29+in+the+EGFR+tyrosine+kinase+domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2eZCxWjJuRRE0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520of%2520EGFR-mutant%2520lung%2520cancer%2520to%2520a%2520T790M-specific%2520EGFR%2520inhibitor%253A%2520Emergence%2520of%2520a%2520third%2520mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DJAMA%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e45</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26749488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e45-47&author=H.+N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=W.+Parkauthor=M.+J.+Ahn&title=Acquired+C797S+mutation+upon+treatment+with+a+T790M-specific+third-generation+EGFR+inhibitor+%28HM61713%29+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%2BN.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DAcquired%2520C797S%2520mutation%2520upon%2520treatment%2520with%2520a%2520T790M-specific%2520third-generation%2520EGFR%2520inhibitor%2520%2528HM61713%2529%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De45%26epage%3D47%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">JCO2017747576</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28841389" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=JCO2017747576&author=S.+S.+Ramalingamauthor=J.+C.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.+W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+C.+Barrettauthor=K.+S.+Thressauthor=P.+A.+Janne&title=Osimertinib+as+first-line+treatment+of+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520of%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26spage%3DJCO2017747576%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moores, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushey, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luistro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brezski, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haytko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neijssen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parren, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. M.</span></span> <span> </span><span class="NLM_article-title">A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3942</span>– <span class="NLM_lpage">3953</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-15-2833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27216193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3942-3953&author=S.+L.+Mooresauthor=M.+L.+Chiuauthor=B.+S.+Busheyauthor=K.+Chevalierauthor=L.+Luistroauthor=K.+Dornauthor=R.+J.+Brezskiauthor=P.+Haytkoauthor=T.+Kellyauthor=S.+J.+Wuauthor=P.+L.+Martinauthor=J.+Neijssenauthor=P.+W.+Parrenauthor=J.+Schuurmanauthor=R.+M.+Attarauthor=S.+Laquerreauthor=M.+V.+Lorenziauthor=G.+M.+Anderson&title=A+novel+bispecific+antibody+targeting+EGFR+and+cMet+is+effective+against+EGFR+inhibitor-resistant+lung+tumors&doi=10.1158%2F0008-5472.CAN-15-2833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors</span></div><div class="casAuthors">Moores, Sheri L.; Chiu, Mark L.; Bushey, Barbara S.; Chevalier, Kristen; Luistro, Leopoldo; Dorn, Keri; Brezski, Randall J.; Haytko, Peter; Kelly, Thomas; Wu, Sheng-Jiun; Martin, Pauline L.; Neijssen, Joost; Parren, Paul W. H. I.; Schuurman, Janine; Attar, Ricardo M.; Laquerre, Sylvie; Lorenzi, Matthew V.; Anderson, G. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3942-3953</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway.  We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multiple mechanisms of action to inhibit primary/secondary EGFR mutations and the cMet pathway.  JNJ-61186372 blocked ligand-induced phosphorylation of EGFR and cMet and inhibited phospho-ERK and phospho-AKT more potently than the combination of single receptor-binding antibodies.  In NSCLC tumor models driven by EGFR and/or cMet, JNJ-61186372 treatment resulted in tumor regression through inhibition of signaling/receptor downmodulation and Fc-driven effector interactions.  Complete and durable regression of human lung xenograft tumors was obsd. with the combination of JNJ-61186372 and a third-generation EGFR TKI.  Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no major toxicities, including absence of skin rash obsd. with other EGFR-directed agents.  These results highlight the differentiated potential of JNJ-61186372 to inhibit the spectrum of mutations driving EGFR TKI resistance in NSCLC.  Cancer Res; 76(13); 3942-53. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO31K0yT1EPrVg90H21EOLACvtfcHk0liTseBCn0AzJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bE&md5=4af4b3eaf60457ad8b87949556f48397</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2833%26sid%3Dliteratum%253Aachs%26aulast%3DMoores%26aufirst%3DS.%2BL.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DBushey%26aufirst%3DB.%2BS.%26aulast%3DChevalier%26aufirst%3DK.%26aulast%3DLuistro%26aufirst%3DL.%26aulast%3DDorn%26aufirst%3DK.%26aulast%3DBrezski%26aufirst%3DR.%2BJ.%26aulast%3DHaytko%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DP.%2BL.%26aulast%3DNeijssen%26aufirst%3DJ.%26aulast%3DParren%26aufirst%3DP.%2BW.%26aulast%3DSchuurman%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DAnderson%26aufirst%3DG.%2BM.%26atitle%3DA%2520novel%2520bispecific%2520antibody%2520targeting%2520EGFR%2520and%2520cMet%2520is%2520effective%2520against%2520EGFR%2520inhibitor-resistant%2520lung%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3942%26epage%3D3953%26doi%3D10.1158%2F0008-5472.CAN-15-2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.12.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.21037%2Ftlcr.2016.12.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28149764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=695-708&author=R.+Minariauthor=P.+Bordiauthor=M.+Tiseo&title=Third-generation+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+T790M-positive+non-small+cell+lung+cancer%3A+review+on+emerged+mechanisms+of+resistance&doi=10.21037%2Ftlcr.2016.12.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span></div><div class="casAuthors">Minari, Roberta; Bordi, Paola; Tiseo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-708</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-pos. non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib.  Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approx. 10 mo.  Mechanisms detg. progression of disease are heterogeneous and not fully understood.  EGFR-dependent resistance mechanisms (such as new EGFR mutations), bypass pathway activation [as erb-b2 receptor tyrosine kinase 2 (HER2) or MET amplification] and histol. transformation [in small cell lung cancer (SCLC)] have been reported, similarly to previous generation TKIs.  Here, we review principle mechanisms of innate and acquired resistance described in literature both in clin. and preclin. settings during NSCLC treatment with third-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELenka7GwYrVg90H21EOLACvtfcHk0liTseBCn0AzJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D&md5=b40df5074fe4944594507d6f3b4f24dd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.12.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.12.02%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DThird-generation%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520review%2520on%2520emerged%2520mechanisms%2520of%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26spage%3D695%26epage%3D708%26doi%3D10.21037%2Ftlcr.2016.12.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0ljWCqnSQ23rcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Brief Report: lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Brief+Report%3A+lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first+and+third+generation+EGFR-TKIs+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2eYXhT_1fWOZrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DBrief%2520Report%253A%2520lung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first%2520and%2520third%2520generation%2520EGFR-TKIs%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural pharmacological studies on EGFR T790M/C797S</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.bbrc.2017.04.138" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2017&pages=266-272&author=L.+L.+Kongauthor=R.+Maauthor=M.+Y.+Yaoauthor=X.+E.+Yanauthor=S.+J.+Zhuauthor=P.+Zhaoauthor=C.+H.+Yun&title=Structural+pharmacological+studies+on+EGFR+T790M%2FC797S&doi=10.1016%2Fj.bbrc.2017.04.138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.138%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520pharmacological%2520studies%2520on%2520EGFR%2520T790M%252FC797S%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D488%26spage%3D266%26epage%3D272%26doi%3D10.1016%2Fj.bbrc.2017.04.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lg5P82woBJYkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.canlet.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27840244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=51-54&author=S.+Wangauthor=Y.+Songauthor=D.+Liu&title=EAI045%3A+The+fourth-generation+EGFR+inhibitor+overcoming+T790M+and+C797S+resistance&doi=10.1016%2Fj.canlet.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span></div><div class="casAuthors">Wang, Shuhang; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-54</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M pos. non-small cell lung cancer (NSCLC).  However, resistance develops rapidly.  EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors.  This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2GMAIDfgfeLVg90H21EOLACvtfcHk0lgXNk73Bnkpig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM&md5=e429055412bec2ec2da28b2b959753ae</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEAI045%253A%2520The%2520fourth-generation%2520EGFR%2520inhibitor%2520overcoming%2520T790M%2520and%2520C797S%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D51%26epage%3D54%26doi%3D10.1016%2Fj.canlet.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span> </span><span class="NLM_article-title">Allosteric EGFR inhibitors overcome resistance mutations</span>.  <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">6</span>,  <span class="NLM_fpage">691</span>. DOI: <span class="refDoi"> DOI: 10.1158/2159-8290.CD-RW2016-104</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-RW2016-104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allosteric+EGFR+inhibitors+overcome+resistance+mutations.+Cancer+Discovery+2016%2C+6%2C+691.+DOI%3A+10.1158%2F2159-8290.CD-RW2016-104."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-RW2016-104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-RW2016-104%26sid%3Dliteratum%253Aachs%26atitle%3DAllosteric%2520EGFR%2520inhibitors%2520overcome%2520resistance%2520mutations%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D691%26doi%3D10.1158%2F2159-8290.CD-RW2016-104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgXNk73Bnkpig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitor profiling reveals unexpected opportunities to inhibit disease-associated mutant kinases</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.celrep.2015.12.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26776524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=772-781&author=K.+C.+Duong-Lyauthor=K.+Devarajanauthor=S.+Liangauthor=K.+Y.+Horiuchiauthor=Y.+Wangauthor=H.+Maauthor=J.+R.+Peterson&title=Kinase+inhibitor+profiling+reveals+unexpected+opportunities+to+inhibit+disease-associated+mutant+kinases&doi=10.1016%2Fj.celrep.2015.12.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Devarajan, Karthik; Liang, Shuguang; Horiuchi, Kurumi Y.; Wang, Yuren; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">772-781</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer.  Mutations can have serious clin. implications by increasing kinase catalytic activity or conferring therapeutic resistance.  To identify opportunities to repurpose inhibitors against disease-assocd. mutant kinases, we conducted a large-scale functional screen of 183 known kinase inhibitors against 76 recombinant mutant kinases.  The results revealed lead compds. with activity against clin. important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for addnl. indications.  Furthermore, using T674I PDGFRα as an example, we show how single-dose screening data can provide predictive structure-activity data to guide subsequent inhibitor optimization.  This study provides a resource for the development of inhibitors against numerous disease-assocd. mutant kinases and illustrates the potential of unbiased profiling as an approach to compd.-centric inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXqJUD9YoWLVg90H21EOLACvtfcHk0lhMBDcMVBwmVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D&md5=b01e8f6ce2aa441400531399d8cf88fc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DHoriuchi%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DKinase%2520inhibitor%2520profiling%2520reveals%2520unexpected%2520opportunities%2520to%2520inhibit%2520disease-associated%2520mutant%2520kinases%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D772%26epage%3D781%26doi%3D10.1016%2Fj.celrep.2015.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0lhMBDcMVBwmVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koivunen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weremowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6051</span>– <span class="NLM_lpage">6060</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-11-1340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=J.+Koivunenauthor=A.+Oginoauthor=M.+Yanagitaauthor=S.+Nikiforowauthor=W.+Zhengauthor=C.+Lathanauthor=J.+P.+Marcouxauthor=J.+Duauthor=K.+Okudaauthor=M.+Capellettiauthor=T.+Shimamuraauthor=D.+Ercanauthor=M.+Stumpfovaauthor=Y.+Xiaoauthor=S.+Weremowiczauthor=M.+Butaneyauthor=S.+Heonauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=M.+J.+Eckauthor=K.+K.+Wongauthor=N.+Lindemanauthor=N.+S.+Grayauthor=S.+J.+Rodigauthor=P.+A.+Janne&title=A+novel+ALK+secondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-11-1340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1340%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKoivunen%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DYanagita%26aufirst%3DM.%26aulast%3DNikiforow%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DLathan%26aufirst%3DC.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DStumpfova%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DHeon%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520secondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060%26doi%3D10.1158%2F0008-5472.CAN-11-1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5686</span>– <span class="NLM_lpage">5696</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0lgnwGTNIxumHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520novel%2520ALK%2520mutations%2520mediate%2520acquired%2520resistance%2520to%2520the%2520next-generation%2520ALK%2520inhibitor%2520alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakody, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0lhYhtEVZGhQNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31313</span>– <span class="NLM_lpage">31322</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.5182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26375053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31313-31322&author=H.+Wuauthor=A.+Wangauthor=W.+Zhangauthor=B.+Wangauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=Z.+Yeauthor=Z.+Zhaoauthor=L.+Wangauthor=X.+Liauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=X.+E.+Yanauthor=P.+Zhaoauthor=J.+Wangauthor=C.+Wangauthor=E.+L.+Weisbergauthor=N.+S.+Grayauthor=C.+H.+Yunauthor=J.+Liuauthor=L.+Chenauthor=Q.+Liu&title=Ibrutinib+selectively+and+irreversibly+targets+EGFR+%28L858R%2C+Del19%29+mutant+but+is+moderately+resistant+to+EGFR+%28T790M%29+mutant+NSCLC+cells&doi=10.18632%2Foncotarget.5182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span></div><div class="casAuthors">Wu Hong; Wang Aoli; Wang Beilei; Chen Cheng; Wang Wenchao; Hu Chen; Zhao Zheng; Wang Li; Li Xixiang; Yu Kailin; Liu Juan; Wu Jiaxin; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Wu Jiaxin; Liu Qingsong; Zhang Wei; Chen Liang; Ye Zi; Wang Chu; Yan Xiao-E; Zhao Peng; Yun Cai-Hong; Wang Jinhua; Gray Nathanael S; Weisberg Ellen L; Liu Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">31313-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M 'gatekeeper' mutant cells and not active to wild-type EGFR NSCLC cells.  Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells.  However, ibrutinib only slowed down tumor progression in PC-9 and H1975 xenograft models.  MEK kinase inhibitor, GSK1120212, could potentiate ibrutinib's effect against the EGFR (L858R/T790M) mutation in vitro but not in vivo.  These results suggest that special drug administration might be required to achieve best clinical response in the ongoing phase I/II clinical trial with ibrutinib for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaJLK7Cf3HfUQ0lWbKiCflfW6udTcc2eZVpy0kdFPsR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D&md5=0b66524bf32eb7fb11ace0b226bbe894</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520and%2520irreversibly%2520targets%2520EGFR%2520%2528L858R%252C%2520Del19%2529%2520mutant%2520but%2520is%2520moderately%2520resistant%2520to%2520EGFR%2520%2528T790M%2529%2520mutant%2520NSCLC%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D31313%26epage%3D31322%26doi%3D10.18632%2Foncotarget.5182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a novel irreversible EGFR mutant kinase inhibitor with a distinct binding mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2944</span>– <span class="NLM_lpage">2962</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2944-2962&author=A.+Wangauthor=X.+Liauthor=H.+Wuauthor=F.+Zouauthor=X.+E.+Yanauthor=C.+Chenauthor=C.+Huauthor=K.+Yuauthor=W.+Wangauthor=P.+Zhaoauthor=J.+Wuauthor=Z.+Qiauthor=W.+Wangauthor=B.+Wangauthor=L.+Wangauthor=T.+Renauthor=S.+Zhangauthor=C.+H.+Yunauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-Amino-3-%283-chloro-4-%28pyridin-2-ylmethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29prop-2-en-1-one+%28CHMFL-EGFR-202%29+as+a+novel+irreversible+EGFR+mutant+kinase+inhibitor+with+a+distinct+binding+mode&doi=10.1021%2Facs.jmedchem.6b01907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-Amino-3-%25283-chloro-4-%2528pyridin-2-ylmethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529prop-2-en-1-one%2520%2528CHMFL-EGFR-202%2529%2520as%2520a%2520novel%2520irreversible%2520EGFR%2520mutant%2520kinase%2520inhibitor%2520with%2520a%2520distinct%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2944%26epage%3D2962%26doi%3D10.1021%2Facs.jmedchem.6b01907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0lhoVYvCLXC0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+frozen+analogue+approach+to+aminopyridinylimidazoles+leading+to+novel+and+promising+p38+MAP+kinase+inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520frozen%2520analogue%2520approach%2520to%2520aminopyridinylimidazoles%2520leading%2520to%2520novel%2520and%2520promising%2520p38%2520MAP%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2eZKe0fc24-2krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an example of target hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&author=M.+Juchumauthor=M.+Guntherauthor=E.+Doringauthor=A.+Sievers-Englerauthor=M.+Lammerhoferauthor=S.+Laufer&title=Trisubstituted+imidazoles+with+a+rigidized+hinge+binding+motif+act+as+single+digit+nM+inhibitors+of+clinically+relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+mutants%3A+an+example+of+target+hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0lgkZtxlMXpi9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DLammerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520imidazoles%2520with%2520a%2520rigidized%2520hinge%2520binding%2520motif%2520act%2520as%2520single%2520digit%2520nM%2520inhibitors%2520of%2520clinically%2520relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520mutants%253A%2520an%2520example%2520of%2520target%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnnt1Gruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&author=M.+Guntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+Doringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Doring Eva; Laufer Stefan; Lategahn Jonas; Keul Marina; Engel Julian; Tumbrink Hannah L; Rauh Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by molecular modeling, we synthesized and studied the structure-activity relationship of 40 compounds against clinically relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6QNTeHCYzDBJ5E29YNGvQfW6udTcc2eYCErYE-1t3gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnnt1Gruw%253D%253D&md5=24b2db3f9206927b546a2a0c8fc05b2a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF receptor inhibitors that are selective for the d746-750/T790M/C797S mutant through structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+receptor+inhibitors+that+are+selective+for+the+d746-750%2FT790M%2FC797S+mutant+through+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520receptor%2520inhibitors%2520that%2520are%2520selective%2520for%2520the%2520d746-750%252FT790M%252FC797S%2520mutant%2520through%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Callejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrente, M.</span></span> <span> </span><span class="NLM_article-title">Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.10.07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.21037%2Ftlcr.2016.10.07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27826527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWrtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=455-465&author=D.+Perez-Callejoauthor=A.+Romeroauthor=M.+Provencioauthor=M.+Torrente&title=Liquid+biopsy+based+biomarkers+in+non-small+cell+lung+cancer+for+diagnosis+and+treatment+monitoring&doi=10.21037%2Ftlcr.2016.10.07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring</span></div><div class="casAuthors">Perez-Callejo, David; Romero, Atocha; Provencio, Mariano; Torrente, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-465</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Advances in the knowledge of the biol. of non-small cell lung cancer (NSCLC) have revealed mol. information used for systemic cancer therapy targeting metastatic disease, with an important impact on patients overall survival (OS) and quality of life.  However, a biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic.  Moreover, a single biopsy cannot reflect the clonal heterogeneity of the tumor.  The anal. of peripheral blood samples of cancer patients represents a new source of cancer-derived material, known as liq. biopsy, and its components can be obtained from almost all body fluids.  These components have shown to reflect characteristics of the status of both the primary and metastatic diseases, helping the clinicians to move towards a personalized medicine.  The present review focuses on the liq. biopsy components: circulating tumor cells (CTCS), circulating free DNA (cfDNA), exosomes and tumor-educated platelets (TEP); the isolation technologies used and their potential use for non-invasive screening, early diagnosis, prognosis, response to treatment and real time monitoring of the disease, in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD34ytsPjw3LVg90H21EOLACvtfcHk0lgBpHqLfpcCtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWrtL%252FN&md5=131043a2b366887ed55d5e616d52cfe7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.10.07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.10.07%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Callejo%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DTorrente%26aufirst%3DM.%26atitle%3DLiquid%2520biopsy%2520based%2520biomarkers%2520in%2520non-small%2520cell%2520lung%2520cancer%2520for%2520diagnosis%2520and%2520treatment%2520monitoring%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26spage%3D455%26epage%3D465%26doi%3D10.21037%2Ftlcr.2016.10.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Integrating liquid biopsies into the management of cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2017.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28252003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=531-548&author=G.+Siravegnaauthor=S.+Marsoniauthor=S.+Sienaauthor=A.+Bardelli&title=Integrating+liquid+biopsies+into+the+management+of+cancer&doi=10.1038%2Fnrclinonc.2017.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating liquid biopsies into the management of cancer</span></div><div class="casAuthors">Siravegna, Giulia; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">531-548</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">During cancer progression and treatment, multiple subclonal populations of tumor cells compete with one another, with selective pressures leading to the emergence of predominant subclones that replicate and spread most proficiently, and are least susceptible to treatment.  At present, the mol. landscapes of solid tumors are established using surgical or biopsy tissue samples.  Tissue-based tumor profiles are, however, subject to sampling bias, provide only a snapshot of tumor heterogeneity, and cannot be obtained repeatedly.  Genomic profiles of circulating cell-free tumor DNA (ctDNA) have been shown to closely match those of the corresponding tumors, with important implications for both mol. pathol. and clin. oncol.  Analyses of circulating nucleic acids, commonly referred to as 'liq. biopsies', can be used to monitor response to treatment, assess the emergence of drug resistance, and quantify minimal residual disease.  In addn. to blood, several other body fluids, such as urine, saliva, pleural effusions, and cerebrospinal fluid, can contain tumor-derived genetic information.  The mol. profiles gathered from ctDNA can be further complemented with those obtained through anal. of circulating tumor cells (CTCs), as well as RNA, proteins, and lipids contained within vesicles, such as exosomes.  In this Review, we examine how different forms of liq. biopsies can be exploited to guide patient care and should ultimately be integrated into clin. practice, focusing on liq. biopsy of ctDNA - arguably the most clin. advanced approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu8wceypGSLVg90H21EOLACvtfcHk0lj0ct9K9rNczg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSns7g%253D&md5=b130fd260e8ef3b239229ccd4fbb81bc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.14%26sid%3Dliteratum%253Aachs%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DIntegrating%2520liquid%2520biopsies%2520into%2520the%2520management%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D531%26epage%3D548%26doi%3D10.1038%2Fnrclinonc.2017.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J. B.</span></span> <span> </span><span class="NLM_article-title">Accessing genetic information with liquid biopsies</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.tig.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.tig.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26450339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=564-575&author=X.+Caiauthor=F.+Jankuauthor=Q.+Zhanauthor=J.+B.+Fan&title=Accessing+genetic+information+with+liquid+biopsies&doi=10.1016%2Fj.tig.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Accessing Genetic Information with Liquid Biopsies</span></div><div class="casAuthors">Cai, Xuyu; Janku, Filip; Zhan, Qimin; Fan, Jian-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">564-575</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a solid foundation for the development of routine mol. liq. biopsies.  This approach provides non-invasive access to genetic information - somatic mutations, epigenetic changes, and differential expression - about the physiol. conditions of the body and diseases.  It opens a valuable avenue for future genetic studies and human disease diagnosis, including prenatal and neurodegenerative disease diagnosis, as well as for cancer screening and monitoring.  With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, mol. liq. biopsies will quickly become a central piece in the future of precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj9lO8vypFNbVg90H21EOLACvtfcHk0lj0ct9K9rNczg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjtr%252FN&md5=f7350be4f0a941743175b9476080fbf2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DZhan%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DJ.%2BB.%26atitle%3DAccessing%2520genetic%2520information%2520with%2520liquid%2520biopsies%26jtitle%3DTrends%2520Genet.%26date%3D2015%26volume%3D31%26spage%3D564%26epage%3D575%26doi%3D10.1016%2Fj.tig.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oellerich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walson, P. D.</span></span> <span> </span><span class="NLM_article-title">Using circulating cell-free DNA to monitor personalized cancer therapy</span>. <i>Crit. Rev. Clin. Lab. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1080/10408363.2017.1299683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1080%2F10408363.2017.1299683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28393575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=205-218&author=M.+Oellerichauthor=E.+Schutzauthor=J.+Beckauthor=P.+Kanzowauthor=P.+N.+Plowmanauthor=G.+J.+Weissauthor=P.+D.+Walson&title=Using+circulating+cell-free+DNA+to+monitor+personalized+cancer+therapy&doi=10.1080%2F10408363.2017.1299683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Using circulating cell-free DNA to monitor personalized cancer therapy</span></div><div class="casAuthors">Oellerich, Michael; Schuetz, Ekkehard; Beck, Julia; Kanzow, Philipp; Plowman, Piers N.; Weiss, Glen J.; Walson, Philip D.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-218</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">High-quality genomic anal. is crit. for personalized pharmacotherapy in patients with cancer.  Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time mol. monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be esp. useful when tumor tissue is unavailable or insufficient for testing.  For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied.  The US Food and Drug Administration (FDA) recently approved the first such "liq. biopsy" test for EGFR mutations in patients with non-small cell lung cancer (NSCLC).  Such non-invasive methods allow for the identification of specific resistance mutations selected by treatment, such as EGFR T790M, in patients with NSCLC treated with gefitinib.  Chromosomal aberration pattern anal. by low coverage whole genome sequencing is a more universal approach based on genomic instability.  Gains and losses of chromosomal regions have been detected in plasma tumor-specific cfDNA as copy no. aberrations and can be used to compute a genomic copy no. instability (CNI) score of cfDNA.  A specific CNI index obtained by massive parallel sequencing discriminated those patients with prostate cancer from both healthy controls and men with benign prostatic disease.  Furthermore, androgen receptor gene aberrations in cfDNA were assocd. with therapeutic resistance in metastatic castration resistant prostate cancer.  Change in CNI score has been shown to serve as an early predictor of response to std. chemotherapy for various other cancer types (e.g. NSCLC, colorectal cancer, pancreatic ductal adenocarcinomas).  CNI scores have also been shown to predict therapeutic responses to immunotherapy.  Serial genomic profiling can detect resistance mutations up to 16 wk before radiog. progression.  There is a potential for cost savings when ineffective use of expensive new anticancer drugs is avoided or halted.  Challenges for routine implementation of liq. biopsy tests include the necessity of specialized personnel, instrumentation, and software, as well as further development of quality management (e.g. external quality control).  Validation of blood-based tumor genomic profiling in addnl. multicenter outcome studies is necessary; however, cfDNA monitoring can provide clin. important actionable information for precision oncol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIOOUvcx_lMbVg90H21EOLACvtfcHk0ljiuuiFOoP4sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVGit7o%253D&md5=f4a51703f5787842de448e40595e5f53</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1080%2F10408363.2017.1299683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408363.2017.1299683%26sid%3Dliteratum%253Aachs%26aulast%3DOellerich%26aufirst%3DM.%26aulast%3DSchutz%26aufirst%3DE.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DKanzow%26aufirst%3DP.%26aulast%3DPlowman%26aufirst%3DP.%2BN.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DWalson%26aufirst%3DP.%2BD.%26atitle%3DUsing%2520circulating%2520cell-free%2520DNA%2520to%2520monitor%2520personalized%2520cancer%2520therapy%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2017%26volume%3D54%26spage%3D205%26epage%3D218%26doi%3D10.1080%2F10408363.2017.1299683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovelet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howarth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagnol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluthgen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicotra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span> <span> </span><span class="NLM_article-title">Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1093%2Fannonc%2Fmdx017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28104619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1c7nsVKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=784-790&author=J.+Remonauthor=C.+Caramellaauthor=C.+Joveletauthor=L.+Lacroixauthor=A.+Lawsonauthor=S.+Smalleyauthor=K.+Howarthauthor=D.+Galeauthor=E.+Greenauthor=V.+Plagnolauthor=N.+Rosenfeldauthor=D.+Planchardauthor=M.+V.+Bluthgenauthor=A.+Gazzahauthor=C.+Pannetauthor=C.+Nicotraauthor=E.+Auclinauthor=J.+C.+Soriaauthor=B.+Besse&title=Osimertinib+benefit+in+EGFR-mutant+NSCLC+patients+with+T790M-mutation+detected+by+circulating+tumour+DNA&doi=10.1093%2Fannonc%2Fmdx017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA</span></div><div class="casAuthors">Remon J; Planchard D; Bluthgen M V; Gazzah A; Pannet C; Nicotra C; Auclin E; Soria J C; Besse B; Caramella C; Jovelet C; Lacroix L; Lawson A; Smalley S; Howarth K; Gale D; Green E; Plagnol V; Rosenfeld N; Gale D; Rosenfeld N; Rosenfeld N; Soria J C; Besse B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">784-790</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation.  Osimertinib is the standard of care in this situation.  The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients.  Material and methods:  ctDNA T790M mutational status was assessed by Inivata InVision® (eTAm-Seq®) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016.  Progressing T790M-positive NSCLC patients received osimertinib (80 mg daily).  The objectives were to assess the response rate to osimertinib according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, the progression-free survival (PFS) on osimertinib, and the percentage of T790M positive in ctDNA.  Results:  The ctDNA T790M mutation was detected in 50% of NSCLC patients.  Among assessable patients, osimertinib gave a partial response rate of 62.5% and a stable disease rate of 37.5%.  All responses were confirmed responses.  After median follow up of 8 months, median PFS by RECIST criteria was not achieved (95% CI: 4-NA), with 6- and 12-months PFS of 66.7% and 52%, respectively.  Conclusion(s):  ctDNA from liquid biopsy can be used as a surrogate marker for T790M in tumour tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOB3-KrCiLUrP3FVUi_gf8fW6udTcc2ea5ghVh1pmvj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7nsVKjsg%253D%253D&md5=57f6c1771b8b77f5cb95715dd13d9aac</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx017%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DCaramella%26aufirst%3DC.%26aulast%3DJovelet%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DLawson%26aufirst%3DA.%26aulast%3DSmalley%26aufirst%3DS.%26aulast%3DHowarth%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DRosenfeld%26aufirst%3DN.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DBluthgen%26aufirst%3DM.%2BV.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DPannet%26aufirst%3DC.%26aulast%3DNicotra%26aufirst%3DC.%26aulast%3DAuclin%26aufirst%3DE.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DBesse%26aufirst%3DB.%26atitle%3DOsimertinib%2520benefit%2520in%2520EGFR-mutant%2520NSCLC%2520patients%2520with%2520T790M-mutation%2520detected%2520by%2520circulating%2520tumour%2520DNA%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D784%26epage%3D790%26doi%3D10.1093%2Fannonc%2Fmdx017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">The clinical development of MEK inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24840079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=385-400&author=Y.+Zhaoauthor=A.+A.+Adjei&title=The+clinical+development+of+MEK+inhibitors&doi=10.1038%2Fnrclinonc.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical development of MEK inhibitors</span></div><div class="casAuthors">Zhao, Yujie; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-400</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers.  As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell proliferation and inhibition of apoptosis and, therefore, MEK1/2 inhibition is an attractive therapeutic strategy in a no. of cancers.  Highly selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have been developed and assessed in numerous clin. studies over the past decade.  These agents are not efficacious in a broad range of unselected cancers, although single-agent antitumor activity has been detected mainly in tumors that harbor mutations in genes encoding the members of the RAS and RAF protein families, such as certain melanomas.  Combinations of MEK1/2 inhibitors and cytotoxic chemotherapy, and/or other targeted agents are being studied to expand the efficacy of this class of agents.  Identifying predictive biomarkers, and delineating de novo and acquired resistance mechanisms are essential for the future clin. development of MEK inhibitors.  We discuss the clin. experience with MEK inhibitors to date, and consider the novel approaches to MEK-inhibitor therapy that might improve outcomes and lead to the wider use of such treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjbK3B6OzVbVg90H21EOLACvtfcHk0ljNORnohM4Evg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D&md5=c81e0a5f52a8d4d482b7d617901d67eb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DThe%2520clinical%2520development%2520of%2520MEK%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D385%26epage%3D400%26doi%3D10.1038%2Fnrclinonc.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussenius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defina, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manalo, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span> <span> </span><span class="NLM_article-title">Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.+C.+Manaloauthor=J.+F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+carboxamide-based+allosteric+MEK+inhibitors%3A+discovery+and+optimization+efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0ljNORnohM4Evg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.%2BC.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520carboxamide-based%2520allosteric%2520MEK%2520inhibitors%253A%2520discovery%2520and%2520optimization%2520efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 45 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean T. Toenjes, Valeria Garcia, Sean M. Maddox, Gregory A. Dawson, Maria A. Ortiz, F. Javier Piedrafita, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 1930-1939. <a href="https://doi.org/10.1021/acschembio.9b00407" title="DOI URL">https://doi.org/10.1021/acschembio.9b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DLeveraging%252BAtropisomerism%252Bto%252BObtain%252Ba%252BSelective%252BInhibitor%252Bof%252BRET%252BKinase%252Bwith%252BSecondary%252BActivities%252Btoward%252BEGFR%252BMutants%26aulast%3DToenjes%26aufirst%3DSean%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D19082019%26date%3D29082019%26date%3D19082019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiannan Li, Tao Zhang, Shiliang Li, Linjiang Tong, Junyu Li, Zhicheng Su, Fang Feng, Deheng Sun, Yi Tong, Xia Wang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Honglin Li, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Yufang Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (6)
                                     , 869-873. <a href="https://doi.org/10.1021/acsmedchemlett.8b00564" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BNoncovalent%252BReversible%252BEGFR%252BKinase%252BInhibitors%252Bof%252BEGFRL858R%25252FT790M%25252FC797S%26aulast%3DLi%26aufirst%3DQiannan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D21052019%26date%3D29052019%26date%3D22052019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yilan Ju, Jintao Wu, Xi Yuan, Luqing Zhao, Ganlin Zhang, Chao Li, <span class="NLM_string-name hlFld-ContribAuthor">Renzhong Qiao</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (24)
                                     , 11372-11383. <a href="https://doi.org/10.1021/acs.jmedchem.8b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BEvaluation%252Bof%252BPotent%252BEGFR%252BInhibitors%252Bthrough%252Bthe%252BIncorporation%252Bof%252BMacrocyclic%252BPolyamine%252BMoieties%252Binto%252Bthe%252B4-Anilinoquinazoline%252BScaffold%26aulast%3DJu%26aufirst%3DYilan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17102018%26date%3D14122018%26date%3D03122018%26volume%3D61%26issue%3D24%26spage%3D11372%26epage%3D11383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Qingshan  Pan</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104848. <a href="https://doi.org/10.1016/j.bioorg.2021.104848" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104848%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Banti-proliferative%252Bactivity%252Bof%252B2-aryl-4-aminoquinazoline%252Bderivatives%252Bas%252BEGFR%252Binhibitors%26aulast%3DZhou%26aufirst%3DZhihui%26date%3D2021%26volume%3D112%26spage%3D104848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Ming  Cai</span>, <span class="hlFld-ContribAuthor ">Liang  Shao</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Kinases Degradation by PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.679120" title="DOI URL">https://doi.org/10.3389/fchem.2021.679120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.679120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.679120%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DTargeting%252BProtein%252BKinases%252BDegradation%252Bby%252BPROTACs%26aulast%3DYu%26aufirst%3DFei%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabriel  Tao</span>, <span class="hlFld-ContribAuthor ">Pavan Kumar  Chityala</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management. </span><span class="cited-content_cbyCitation_journal-name">Toxicology Research</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 476-486. <a href="https://doi.org/10.1093/toxres/tfab026" title="DOI URL">https://doi.org/10.1093/toxres/tfab026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/toxres/tfab026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Ftoxres%2Ftfab026%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%2520Research%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitor-induced%252Bdiarrhea%25253A%252Bclinical%252Bincidence%25252C%252Btoxicological%252Bmechanism%25252C%252Band%252Bmanagement%26aulast%3DTao%26aufirst%3DGabriel%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D476%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojing  Du</span>, <span class="hlFld-ContribAuthor ">Biwei  Yang</span>, <span class="hlFld-ContribAuthor ">Quanlin  An</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Xin  Cao</span>, <span class="hlFld-ContribAuthor ">Jinglin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Innovation</span><span> <strong>2021,</strong> <em>2 </em>
                                    (2)
                                     , 100103. <a href="https://doi.org/10.1016/j.xinn.2021.100103" title="DOI URL">https://doi.org/10.1016/j.xinn.2021.100103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xinn.2021.100103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xinn.2021.100103%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Innovation%26atitle%3DAcquired%252Bresistance%252Bto%252Bthird-generation%252BEGFR-TKIs%252Band%252Bemerging%252Bnext-generation%252BEGFR%252Binhibitors%26aulast%3DDu%26aufirst%3DXiaojing%26date%3D2021%26volume%3D2%26issue%3D2%26spage%3D100103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights into redox-active cysteine residues of the Src family kinases. </span><span class="cited-content_cbyCitation_journal-name">Redox Biology</span><span> <strong>2021,</strong> <em>41 </em>, 101934. <a href="https://doi.org/10.1016/j.redox.2021.101934" title="DOI URL">https://doi.org/10.1016/j.redox.2021.101934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.redox.2021.101934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.redox.2021.101934%26sid%3Dliteratum%253Aachs%26jtitle%3DRedox%2520Biology%26atitle%3DStructural%252Binsights%252Binto%252Bredox-active%252Bcysteine%252Bresidues%252Bof%252Bthe%252BSrc%252Bfamily%252Bkinases%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26volume%3D41%26spage%3D101934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Qiuyue  Zhang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>95 </em><a href="https://doi.org/10.1002/med.21807" title="DOI URL">https://doi.org/10.1002/med.21807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21807%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252Bthe%252BHSP90%2525E2%252580%252593CDC37%2525E2%252580%252593kinase%252Bchaperone%252Bcycle%25253A%252BA%252Bpromising%252Btherapeutic%252Bstrategy%252Bfor%252Bcancer%26aulast%3DWang%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charlotte  Nys</span>, <span class="hlFld-ContribAuthor ">Hugo  Vankelecom</span>. </span><span class="cited-content_cbyCitation_article-title">Pituitary disease and recovery: How are stem cells involved?. </span><span class="cited-content_cbyCitation_journal-name">Molecular and Cellular Endocrinology</span><span> <strong>2021,</strong> <em>525 </em>, 111176. <a href="https://doi.org/10.1016/j.mce.2021.111176" title="DOI URL">https://doi.org/10.1016/j.mce.2021.111176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mce.2021.111176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mce.2021.111176%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520and%2520Cellular%2520Endocrinology%26atitle%3DPituitary%252Bdisease%252Band%252Brecovery%25253A%252BHow%252Bare%252Bstem%252Bcells%252Binvolved%25253F%26aulast%3DNys%26aufirst%3DCharlotte%26date%3D2021%26volume%3D525%26spage%3D111176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Kuojun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yiwu  Yao</span>, <span class="hlFld-ContribAuthor ">Yunyao  Liu</span>, <span class="hlFld-ContribAuthor ">Yong  Ni</span>, <span class="hlFld-ContribAuthor ">Chenzhong  Liao</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yatao  Qiu</span>, <span class="hlFld-ContribAuthor ">Dexiang  Wang</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Qiang</span>, <span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113022. <a href="https://doi.org/10.1016/j.ejmech.2020.113022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bnicotinamide%252Bphosphoribosyltransferase%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DZhang%26aufirst%3DWanheng%26date%3D2021%26volume%3D211%26spage%3D113022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teodora  Djikic</span>, <span class="hlFld-ContribAuthor ">Zarko  Gagic</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Discovery of Kinase Inhibitors Using Docking Studies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 337-365. <a href="https://doi.org/10.1016/B978-0-12-822312-3.00009-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-822312-3.00009-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822312-3.00009-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822312-3.00009-6%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Band%252BDiscovery%252Bof%252BKinase%252BInhibitors%252BUsing%252BDocking%252BStudies%26aulast%3DDjikic%26aufirst%3DTeodora%26date%3D2021%26spage%3D337%26epage%3D365%26pub%3DElsevier%26atitle%3DMolecular%252BDocking%252Bfor%252BComputer-Aided%252BDrug%252BDesign%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenhao  Xu</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Guanjun  Dong</span>, <span class="hlFld-ContribAuthor ">Hui  Qiao</span>, <span class="hlFld-ContribAuthor ">Jiadi  Peng</span>, <span class="hlFld-ContribAuthor ">Pengfei  Jia</span>, <span class="hlFld-ContribAuthor ">Yuhao  Li</span>, <span class="hlFld-ContribAuthor ">Hongmin  Liu</span>, <span class="hlFld-ContribAuthor ">Kai  Sun</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing hydrazone fragment as potent and selective anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>105 </em>, 104424. <a href="https://doi.org/10.1016/j.bioorg.2020.104424" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104424</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104424%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252B%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-d%25255Dpyrimidine%252Bderivatives%252Bcontaining%252Bhydrazone%252Bfragment%252Bas%252Bpotent%252Band%252Bselective%252Banticancer%252Bagents%26aulast%3DXu%26aufirst%3DChenhao%26date%3D2020%26volume%3D105%26spage%3D104424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Xiao-Xiao  Xi</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent small molecule PROTACs targeting mutant EGFR. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112781. <a href="https://doi.org/10.1016/j.ejmech.2020.112781" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112781%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bsmall%252Bmolecule%252BPROTACs%252Btargeting%252Bmutant%252BEGFR%26aulast%3DZhao%26aufirst%3DHong-Yi%26date%3D2020%26volume%3D208%26spage%3D112781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sitanshu S.  Singh</span>, <span class="hlFld-ContribAuthor ">Achyut  Dahal</span>, <span class="hlFld-ContribAuthor ">Leeza  Shrestha</span>, <span class="hlFld-ContribAuthor ">Seetharama D.  Jois</span>. </span><span class="cited-content_cbyCitation_article-title">Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (32)
                                     , 5274-5316. <a href="https://doi.org/10.2174/0929867326666190222183219" title="DOI URL">https://doi.org/10.2174/0929867326666190222183219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190222183219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190222183219%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DGenotype%252BDriven%252BTherapy%252Bfor%252BNon-Small%252BCell%252BLung%252BCancer%25253A%252BResistance%25252C%252BPan%252BInhibitors%252Band%252BImmunotherapy%26aulast%3DSingh%26aufirst%3DSitanshu%2BS.%26date%3D2020%26volume%3D27%26issue%3D32%26spage%3D5274%26epage%3D5316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bao-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Song-Bo  Kou</span>, <span class="hlFld-ContribAuthor ">Zhen-Yi  Lin</span>, <span class="hlFld-ContribAuthor ">Jie-Hua  Shi</span>, <span class="hlFld-ContribAuthor ">Ying-Xin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Insights on the interaction mechanism of brigatinib to human α-1-acid glycoprotein: Experimental and computational approaches. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2020,</strong> <em>157 </em>, 340-349. <a href="https://doi.org/10.1016/j.ijbiomac.2020.04.151" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.04.151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.04.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.04.151%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DInsights%252Bon%252Bthe%252Binteraction%252Bmechanism%252Bof%252Bbrigatinib%252Bto%252Bhuman%252B%2525CE%2525B1-1-acid%252Bglycoprotein%25253A%252BExperimental%252Band%252Bcomputational%252Bapproaches%26aulast%3DWang%26aufirst%3DBao-Li%26date%3D2020%26volume%3D157%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Drug Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-96. <a href="https://doi.org/10.1002/9781119607311.ch1" title="DOI URL">https://doi.org/10.1002/9781119607311.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119607311.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119607311.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BTargets%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D96%26pub%3DWiley%26atitle%3DMedicinal%252BChemistry%252Bfor%252BPractitioners%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2020%26date%3D2020%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shubham  Atal</span>, <span class="hlFld-ContribAuthor ">Pravin  Asokan</span>, <span class="hlFld-ContribAuthor ">Ratinder  Jhaj</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in targeted small‐molecule inhibitor therapy for non–small‐cell lung cancer—An update. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Pharmacy and Therapeutics</span><span> <strong>2020,</strong> <em>45 </em>
                                    (3)
                                     , 580-584. <a href="https://doi.org/10.1111/jcpt.13121" title="DOI URL">https://doi.org/10.1111/jcpt.13121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcpt.13121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcpt.13121%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Pharmacy%2520and%2520Therapeutics%26atitle%3DRecent%252Badvances%252Bin%252Btargeted%252Bsmall%2525E2%252580%252590molecule%252Binhibitor%252Btherapy%252Bfor%252Bnon%2525E2%252580%252593small%2525E2%252580%252590cell%252Blung%252Bcancer%2525E2%252580%252594An%252Bupdate%26aulast%3DAtal%26aufirst%3DShubham%26date%3D2020%26date%3D2020%26volume%3D45%26issue%3D3%26spage%3D580%26epage%3D584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohui  Ren</span>, <span class="hlFld-ContribAuthor ">Xinfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianfei  Yu</span>, <span class="hlFld-ContribAuthor ">Xin  Song</span>, <span class="hlFld-ContribAuthor ">Henghui  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of International Medical Research</span><span> <strong>2020,</strong> <em>48 </em>
                                    (6)
                                     , 030006052092791. <a href="https://doi.org/10.1177/0300060520927918" title="DOI URL">https://doi.org/10.1177/0300060520927918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0300060520927918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0300060520927918%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520International%2520Medical%2520Research%26atitle%3DHistological%252Btransformation%252Bof%252Blung%252Badenocarcinoma%252Bto%252Bsmall%252Bcell%252Blung%252Bcancer%252Bwith%252Bmutant%252BC797S%252Bconferring%252Bacquired%252Bresistance%252Bto%252Bosimertinib%26aulast%3DRen%26aufirst%3DXiaohui%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D6%26spage%3D030006052092791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianglong  Hu</span>, <span class="hlFld-ContribAuthor ">Qiuju  Xun</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Su-Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Tao  Huang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (5)
                                     , 1281-1287. <a href="https://doi.org/10.1016/j.cclet.2019.09.044" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.09.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.09.044%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3D2-Oxo-3%25252C4-dihydropyrimido%25255B4%25252C5-d%25255D%252Bpyrimidines%252Bas%252Bnew%252Breversible%252Binhibitors%252Bof%252BEGFR%252BC797S%252B%252528Cys797%252Bto%252BSer797%252529%252Bmutant%26aulast%3DHu%26aufirst%3DXianglong%26date%3D2020%26volume%3D31%26issue%3D5%26spage%3D1281%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Deepak  Lokwani</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em> </em>, 1-19. <a href="https://doi.org/10.1080/07391102.2020.1754918" title="DOI URL">https://doi.org/10.1080/07391102.2020.1754918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1754918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1754918%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DBREED%252Bbased%252Bde%252Bnovo%252Bhybridization%252Bapproach%25253A%252Bgenerating%252Bnovel%252BT790M%25252FC797S-EGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bto%252Bovercome%252Bthe%252Bproblem%252Bof%252Bmutation%252Band%252Bresistance%252Bin%252Bnon%252Bsmall%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Igor P.  Oscorbin</span>, <span class="hlFld-ContribAuthor ">Alexandra S.  Shadrina</span>, <span class="hlFld-ContribAuthor ">Vadim V.  Kozlov</span>, <span class="hlFld-ContribAuthor ">Vladimir E.  Voitsitsky</span>, <span class="hlFld-ContribAuthor ">Maxim L.  Filipenko</span>. </span><span class="cited-content_cbyCitation_article-title">Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. </span><span class="cited-content_cbyCitation_journal-name">Pathology & Oncology Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (2)
                                     , 1229-1234. <a href="https://doi.org/10.1007/s12253-019-00683-4" title="DOI URL">https://doi.org/10.1007/s12253-019-00683-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12253-019-00683-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12253-019-00683-4%26sid%3Dliteratum%253Aachs%26jtitle%3DPathology%2520%2526%2520Oncology%2520Research%26atitle%3DAbsence%252Bof%252BEGFR%252BC797S%252BMutation%252Bin%252BTyrosine%252BKinase%252BInhibitor-Na%2525C3%2525AFve%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BTissues%26aulast%3DOscorbin%26aufirst%3DIgor%2BP.%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D1229%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaozhi  Chen</span>, <span class="hlFld-ContribAuthor ">Yuyan  Bao</span>, <span class="hlFld-ContribAuthor ">Qiaoyou  Weng</span>, <span class="hlFld-ContribAuthor ">Yingxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyao  Lu</span>, <span class="hlFld-ContribAuthor ">Lili  Fu</span>, <span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaomin  Zhang</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.01533" title="DOI URL">https://doi.org/10.3389/fphar.2019.01533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.01533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.01533%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DCompound%252B15c%25252C%252Ba%252BNovel%252BDual%252BInhibitor%252Bof%252BEGFRL858R%25252FT790M%252Band%252BFGFR1%25252C%252BEfficiently%252BOvercomes%252BEpidermal%252BGrowth%252BFactor%252BReceptor-Tyrosine%252BKinase%252BInhibitor%252BResistance%252Bof%252BNon-Small-Cell%252BLung%252BCancers%26aulast%3DChen%26aufirst%3DGaozhi%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Della Grace Thomas  Parambi</span>, <span class="hlFld-ContribAuthor ">K. M.  Noorulla</span>, <span class="hlFld-ContribAuthor ">Md.  Sahab Uddin</span>, <span class="hlFld-ContribAuthor ">Bijo  Mathew</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal Growth Factor Receptor: Promising Targets for Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 465-471. <a href="https://doi.org/10.1007/978-981-32-9366-3_21" title="DOI URL">https://doi.org/10.1007/978-981-32-9366-3_21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-32-9366-3_21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-32-9366-3_21%26sid%3Dliteratum%253Aachs%26atitle%3DEpidermal%252BGrowth%252BFactor%252BReceptor%25253A%252BPromising%252BTargets%252Bfor%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DParambi%26aufirst%3DDella%2BGrace%2BThomas%26date%3D2020%26date%3D2019%26spage%3D465%26epage%3D471%26pub%3DSpringer%2520Singapore%26atitle%3DOxidative%252BStress%252Bin%252BLung%252BDiseases%26aulast%3DChakraborti%26aufirst%3DSajal%26date%3D2020%26volume%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N. S.  Persky</span>, <span class="hlFld-ContribAuthor ">D.  Hernandez</span>, <span class="hlFld-ContribAuthor ">M.  Do Carmo</span>, <span class="hlFld-ContribAuthor ">L.  Brenan</span>, <span class="hlFld-ContribAuthor ">O.  Cohen</span>, <span class="hlFld-ContribAuthor ">S.  Kitajima</span>, <span class="hlFld-ContribAuthor ">U.  Nayar</span>, <span class="hlFld-ContribAuthor ">A.  Walker</span>, <span class="hlFld-ContribAuthor ">S.  Pantel</span>, <span class="hlFld-ContribAuthor ">Y.  Lee</span>, <span class="hlFld-ContribAuthor ">J.  Cordova</span>, <span class="hlFld-ContribAuthor ">M.  Sathappa</span>, <span class="hlFld-ContribAuthor ">C.  Zhu</span>, <span class="hlFld-ContribAuthor ">T. K.  Hayes</span>, <span class="hlFld-ContribAuthor ">P.  Ram</span>, <span class="hlFld-ContribAuthor ">P.  Pancholi</span>, <span class="hlFld-ContribAuthor ">T. S.  Mikkelsen</span>, <span class="hlFld-ContribAuthor ">D. A.  Barbie</span>, <span class="hlFld-ContribAuthor ">X.  Yang</span>, <span class="hlFld-ContribAuthor ">R.  Haq</span>, <span class="hlFld-ContribAuthor ">F.  Piccioni</span>, <span class="hlFld-ContribAuthor ">D. E.  Root</span>, <span class="hlFld-ContribAuthor ">C. M.  Johannessen</span>. </span><span class="cited-content_cbyCitation_article-title">Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. </span><span class="cited-content_cbyCitation_journal-name">Nature Structural & Molecular Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (1)
                                     , 92-104. <a href="https://doi.org/10.1038/s41594-019-0358-z" title="DOI URL">https://doi.org/10.1038/s41594-019-0358-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41594-019-0358-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41594-019-0358-z%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Structural%2520%2526%2520Molecular%2520Biology%26atitle%3DDefining%252Bthe%252Blandscape%252Bof%252BATP-competitive%252Binhibitor%252Bresistance%252Bresidues%252Bin%252Bprotein%252Bkinases%26aulast%3DPersky%26aufirst%3DN.%2BS.%26date%3D2020%26date%3D2020%26volume%3D27%26issue%3D1%26spage%3D92%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (16)
                                     , 4384-4394. <a href="https://doi.org/10.1080/07391102.2018.1552197" title="DOI URL">https://doi.org/10.1080/07391102.2018.1552197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1552197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1552197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DInsight%252Binto%252Bbinding%252Bmechanisms%252Bof%252BEGFR%252Ballosteric%252Binhibitors%252Busing%252Bmolecular%252Bdynamics%252Bsimulations%252Band%252Bfree%252Benergy%252Bcalculations%26aulast%3DWan%26aufirst%3DShanhe%26date%3D2019%26date%3D2019%26volume%3D37%26issue%3D16%26spage%3D4384%26epage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N. V.  Stolpovskaya</span>, <span class="hlFld-ContribAuthor ">A. A.  Kruzhilin</span>, <span class="hlFld-ContribAuthor ">A. V.  Zorina</span>, <span class="hlFld-ContribAuthor ">Kh. S.  Shikhaliev</span>, <span class="hlFld-ContribAuthor ">I. V.  Ledeneva</span>, <span class="hlFld-ContribAuthor ">E. A.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">D. Yu.  Vandyshev</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Substituted Aminopyrimidines as Novel Promising Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>55 </em>
                                    (9)
                                     , 1322-1328. <a href="https://doi.org/10.1134/S1070428019090094" title="DOI URL">https://doi.org/10.1134/S1070428019090094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428019090094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428019090094%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BSubstituted%252BAminopyrimidines%252Bas%252BNovel%252BPromising%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DStolpovskaya%26aufirst%3DN.%2BV.%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D9%26spage%3D1322%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>, <span class="hlFld-ContribAuthor ">Mallaiah  Keesara</span>, <span class="hlFld-ContribAuthor ">Ashok G.  Moghudula</span>, <span class="hlFld-ContribAuthor ">Pranab  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1435-1439. <a href="https://doi.org/10.1016/j.bmcl.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bgeneration%252Bof%252B1%25252C2-dithiolanes%252Bas%252Bexon%252B19%252Band%252Bexon%252B21%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1435%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart I.  Roman</span>. </span><span class="cited-content_cbyCitation_article-title">Essay: Avoiding unfounded health claims on small molecules in scientific literature. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>86 </em>, 273-276. <a href="https://doi.org/10.1016/j.bioorg.2019.02.002" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DEssay%25253A%252BAvoiding%252Bunfounded%252Bhealth%252Bclaims%252Bon%252Bsmall%252Bmolecules%252Bin%252Bscientific%252Bliterature%26aulast%3DRoman%26aufirst%3DBart%2BI.%26date%3D2019%26volume%3D86%26spage%3D273%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leifang  Liu</span>, <span class="hlFld-ContribAuthor ">Kai  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenbo  Li</span>, <span class="hlFld-ContribAuthor ">Mingli  Liu</span>, <span class="hlFld-ContribAuthor ">Yuting  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of heterobiaryls via Suzuki-Miyaura coupling reaction of potassium aryltrifluoroborates with heteroaryl halides in aqueous systems. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2019,</strong> <em>33 </em>
                                    (4)
                                     , e4831. <a href="https://doi.org/10.1002/aoc.4831" title="DOI URL">https://doi.org/10.1002/aoc.4831</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.4831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.4831%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bheterobiaryls%252Bvia%252BSuzuki-Miyaura%252Bcoupling%252Breaction%252Bof%252Bpotassium%252Baryltrifluoroborates%252Bwith%252Bheteroaryl%252Bhalides%252Bin%252Baqueous%252Bsystems%26aulast%3DLiu%26aufirst%3DLeifang%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D4%26spage%3De4831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , e1800518. <a href="https://doi.org/10.1002/cbdv.201800518" title="DOI URL">https://doi.org/10.1002/cbdv.201800518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201800518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201800518%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DCovalent%252Bvs.%252BNon%2525E2%252580%252590Covalent%252BInhibition%25253A%252BTackling%252BDrug%252BResistance%252Bin%252BEGFR%252B%2525E2%252580%252593%252BA%252BThorough%252BDynamic%252BPerspective%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3De1800518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marwa Ali A.  Fathi</span>, <span class="hlFld-ContribAuthor ">Amer Ali  Abd El-Hafeez</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Samar H.  Abbas</span>, <span class="hlFld-ContribAuthor ">Monica M.  Montano</span>, <span class="hlFld-ContribAuthor ">Mohamed  Abdel-Aziz</span>. </span><span class="cited-content_cbyCitation_article-title">1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>, 150-163. <a href="https://doi.org/10.1016/j.bioorg.2018.11.032" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.11.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.11.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D1%25252C3%25252C4-oxadiazole%25252Fchalcone%252Bhybrids%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Binhibition%252Bof%252Bleukemia%252Bcell%252Bgrowth%252Band%252BEGFR%25252C%252BSrc%25252C%252BIL-6%252Band%252BSTAT3%252Bactivities%26aulast%3DFathi%26aufirst%3DMarwa%2BAli%2BA.%26date%3D2019%26volume%3D84%26spage%3D150%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tri  Le</span>, <span class="hlFld-ContribAuthor ">David  Gerber</span>. </span><span class="cited-content_cbyCitation_article-title">Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (3)
                                     , 366. <a href="https://doi.org/10.3390/cancers11030366" title="DOI URL">https://doi.org/10.3390/cancers11030366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11030366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11030366%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DNewer-Generation%252BEGFR%252BInhibitors%252Bin%252BLung%252BCancer%25253A%252BHow%252BAre%252BThey%252BBest%252BUsed%25253F%26aulast%3DLe%26aufirst%3DTri%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D3%26spage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiho  Song</span>, <span class="hlFld-ContribAuthor ">Soyeon  Jang</span>, <span class="hlFld-ContribAuthor ">Jung Wuk  Lee</span>, <span class="hlFld-ContribAuthor ">Danbee  Jung</span>, <span class="hlFld-ContribAuthor ">Seul  Lee</span>, <span class="hlFld-ContribAuthor ">Kyung Hoon  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (3)
                                     , 477-480. <a href="https://doi.org/10.1016/j.bmcl.2018.12.020" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.12.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.12.020%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DClick%252Bchemistry%252Bfor%252Bimprovement%252Bin%252Bselectivity%252Bof%252Bquinazoline-based%252Bkinase%252Binhibitors%252Bfor%252Bmutant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptors%26aulast%3DSong%26aufirst%3DJiho%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D477%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong‐Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Brønsted Acid‐Catalyzed Direct C(
              sp
              2
              )−H Heteroarylation Enabling the Synthesis of Structurally Diverse Biaryl Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (1)
                                     , 59-66. <a href="https://doi.org/10.1002/adsc.201801226" title="DOI URL">https://doi.org/10.1002/adsc.201801226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201801226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201801226%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DBr%2525C3%2525B8nsted%252BAcid%2525E2%252580%252590Catalyzed%252BDirect%252BC%252528%252Bsp%252B2%252B%252529%2525E2%252588%252592H%252BHeteroarylation%252BEnabling%252Bthe%252BSynthesis%252Bof%252BStructurally%252BDiverse%252BBiaryl%252BDerivatives%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2019%26date%3D2018%26volume%3D361%26issue%3D1%26spage%3D59%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaling  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Xiabing  Li</span>, <span class="hlFld-ContribAuthor ">Li  Gao</span>, <span class="hlFld-ContribAuthor ">Yunxia  Hao</span>, <span class="hlFld-ContribAuthor ">Baolin  Li</span>, <span class="hlFld-ContribAuthor ">Yaping  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-arylaminoquinazolines bearing
              N
              ,
              N
              -diethyl(aminoethyl)amino moiety with antitumour activity as EGFR
              wt
              -TK inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1668-1677. <a href="https://doi.org/10.1080/14756366.2019.1667341" title="DOI URL">https://doi.org/10.1080/14756366.2019.1667341</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1667341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1667341%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-arylaminoquinazolines%252Bbearing%252BN%252B%25252C%252BN%252B-diethyl%252528aminoethyl%252529amino%252Bmoiety%252Bwith%252Bantitumour%252Bactivity%252Bas%252BEGFR%252Bwt%252B-TK%252Binhibitor%26aulast%3DZhang%26aufirst%3DYaling%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1668%26epage%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Third-generation EGFR-TKIs and their clinical trials status. The image of EGFR T790M/C797S kinase domain was generated by Pymol (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure and binding mode of the allosteric inhibitors. (A) Chemical structure of <b>8</b>. (B) Overall view of <b>8</b> bound to EGFR T790M/V948R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41">5D41</a>). <b>8</b> is shown in green, kinase protein in pink, αC-helix in slate. Hydrogen bond between <b>8</b> and DFG is shown as red dotted line. (C) Chemical structure of <b>9</b>. (D) Overview of the classic EGFR ATP binding pocket (green) and the created allosteric site (yellow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of inhibitors <b>10</b>–<b>15</b> and their cell growth inhibition activities against Ba/F3 cells expressing del19/T790M/C797S EGFR mutants using the CellTiter-Glo assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of inhibitors <b>16</b>–<b>20</b> and their activities against EGFR kinase and its mutants. The enzymes activities of <b>18</b>–<b>20</b> against EGFR kinase and its mutants were performed using HTRF KinEASE-TK assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of inhibitors <b>21</b>–<b>27</b> and their activities against EGFR kinase and its mutants. The enzymes activities of <b>21</b>–<b>27</b> were tested in a radiolabeled 33P(ATP) kinase assay or HTRF KinEASE-TK assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibitors binding with EGFR C797S/T790M mutant: (A) chemical structure of <b>25</b> and its depicted binding mode; (B) binding mode of <b>25</b> with the EGFR C797S/T790M mutant; (C) chemical structure of <b>31</b> and its depicted binding mode; (D) binding mode of <b>31</b> with the EGFR C797S/T790M (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>) mutant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of inhibitors <b>28</b>–<b>31</b> and their activities against EGFR kinase and its mutants using radiolabeled 33P(ATP) kinase assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/medium/jm-2017-01310k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Intratumoral heterogeneity and future treatment paradigm of patients with EGFR mutant NSCLC. Each colored ball represents a distinct clone with newly acquired resistance mechanism.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-10/acs.jmedchem.7b01310/20180517/images/large/jm-2017-01310k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01310&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2017</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3322%2Fcaac.21387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28055103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1c7isFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2017&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics%2C+2017&doi=10.3322%2Fcaac.21387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2017</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States.  For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher.  However, sex disparities vary by cancer type.  For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women.  From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.  Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%).  Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population.  CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSB4oj7vNRTIb5oR8RchjrrfW6udTcc2ebAoDJtRwE3aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7isFWgtA%253D%253D&md5=e439f3424d5a773e4ae289c392236ad6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21387%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202017%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2017%26volume%3D67%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues Pereira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuleanu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thongprasert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maoleekoonpiroj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kooten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dediu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezjak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santabarbara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, L.</span></span> <span> </span><span class="NLM_article-title">National Cancer Institute of Canada Clinical Trials, G. Erlotinib in previously treated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+Rodrigues+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=National+Cancer+Institute+of+Canada+Clinical+Trials%2C+G.+Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0ljUxWAxgAtrMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DRodrigues%2BPereira%26aufirst%3DJ.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DNational%2520Cancer%2520Institute%2520of%2520Canada%2520Clinical%2520Trials%252C%2520G.%2520Erlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0ljUxWAxgAtrMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhdBsQiW72ASQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maemondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukiwa, T.</span></span> <span> </span><span class="NLM_article-title">North-East Japan Study, G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2388</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0909530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=North-East+Japan+Study%2C+G.+Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR&doi=10.1056%2FNEJMoa0909530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lhdBsQiW72ASQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DNorth-East%2520Japan%2520Study%252C%2520G.%2520Gefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388%26doi%3D10.1056%2FNEJMoa0909530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhXRNt8n0vUmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2014.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24981256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=473-481&author=D.+R.+Camidgeauthor=W.+Paoauthor=L.+V.+Sequist&title=Acquired+resistance+to+TKIs+in+solid+tumours%3A+learning+from+lung+cancer&doi=10.1038%2Fnrclinonc.2014.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to TKIs in solid tumours: learning from lung cancer</span></div><div class="casAuthors">Camidge, D. Ross; Pao, William; Sequist, Lecia V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The use of advanced mol. profiling to direct the use of targeted therapy, such as tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer (NSCLC), has revolutionized the treatment of this disease.  However, acquired resistance, defined as progression after initial benefit, to targeted therapies inevitably occurs.  This Review explores breakthroughs in the understanding and treatment of acquired resistance in NSCLC, focusing on EGFR mutant and ALK rearrangement-pos. disease, which may be relevant across multiple different solid malignancies with oncogene-addicted subtypes.  Mechanisms of acquired resistance may be pharmacol. (i.e., failure of delivery of the drug to its target) or biol., resulting from evolutionary selection on molecularly diverse tumors.  A no. of clin. approaches can maintain control of the disease in the acquired resistance setting, including the use of radiation to treat isolated areas of progression and adding or switching to cytotoxic chemotherapy.  Furthermore, novel approaches that have already proven successful include the development of second-generation and third-generation inhibitors and the combination of some of these inhibitors with antibodies directed against the same target.  With our increased understanding of the spectrum of acquired resistance, major changes in how we conduct clin. research in this setting are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00ixSKYoDuLVg90H21EOLACvtfcHk0lhXRNt8n0vUmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWisLrL&md5=13cc2f49f7ef320ad54f7e84f5102816</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.104%26sid%3Dliteratum%253Aachs%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26atitle%3DAcquired%2520resistance%2520to%2520TKIs%2520in%2520solid%2520tumours%253A%2520learning%2520from%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D473%26epage%3D481%26doi%3D10.1038%2Fnrclinonc.2014.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lj1EtIQOyXimA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.,  St</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lj1EtIQOyXimA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N. B.</span></span> <span> </span><span class="NLM_article-title">Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">113</span>, <span class="refDoi"> DOI: 10.3389/fonc.2017.00113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3389%2Ffonc.2017.00113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28620581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=113&author=T.+A.+Barnesauthor=G.+M.+O%E2%80%99Kaneauthor=M.+D.+Vincentauthor=N.+B.+Leighl&title=Third-generation+tyrosine+kinase+inhibitors+targeting+epidermal+growth+factor+receptor+mutations+in+non-small+cell+lung+cancer&doi=10.3389%2Ffonc.2017.00113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Barnes Tristan A; O'Kane Grainne M; Leighl Natasha B; Vincent Mark David</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer.  Eventual resistance develops with multiple mechanisms identifiable both upon repeat biopsy and in plasma circulating tumor DNA.  The T790M gatekeeper mutation is responsible for almost 60% of cases.  A number of third-generation TKIs are in clinical development, and osimertinib has been approved by the US Food and Drug Administration for the treatment of patients with EGFR T790M mutant lung cancer after failure of initial EGFR kinase therapy.  Resistance mechanisms are being identified to these novel agents, and the treatment landscape of EGFR-mutant lung cancer continues to evolve.  The sequence of EGFR TKIs may change in the future and combination therapies targeting resistance appear highly promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT45i3zpRyq-4hLSh9fo81bfW6udTcc2eYqm-44Ni2BALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnovVOnsw%253D%253D&md5=591385d1fc87186675e46ad3621dc82b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2017.00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2017.00113%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DT.%2BA.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DG.%2BM.%26aulast%3DVincent%26aufirst%3DM.%2BD.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26atitle%3DThird-generation%2520tyrosine%2520kinase%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DFront.%2520Oncol.%26date%3D2017%26volume%3D7%26spage%3D113%26doi%3D10.3389%2Ffonc.2017.00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1709</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.+C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eYqm-44Ni2BALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villadolid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ersek, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirianno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Story, E. S.</span></span> <span> </span><span class="NLM_article-title">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">583</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2218-6751.2015.10.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.3978%2Fj.issn.2218-6751.2015.10.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26629426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=576-583&author=J.+Villadolidauthor=J.+L.+Ersekauthor=M.+K.+Fongauthor=L.+Siriannoauthor=E.+S.+Story&title=Management+of+hyperglycemia+from+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29+targeting+T790M-mediated+resistance&doi=10.3978%2Fj.issn.2218-6751.2015.10.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance</span></div><div class="casAuthors">Villadolid, Jeryl; Ersek, Jennifer L.; Fong, Mei Ka; Sirianno, Lindsey; Story, Ellen S.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-583</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to small mol. tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib.  Although studies show an increased progression free survival (PFS) with use of EGFR TKIs in the first-line setting, most patients will develop resistance to therapy after the first 8-16 mo.  T790M is an acquired resistance mutation reported in 60-70% of patients who initially responded to a prior EGFR TKI.  Recently, EGFR TKIs targeting T790M have been developed to overcome resistance with pos. results in PFS and objective response rate in patients who have had disease progression on at least one TKI.  Two EGFR TKIs targeting T790M, AZD9291 and rociletinib, are new active treatment options for NSCLC but differ in adverse effect profiles.  Dose-limiting hyperglycemia has been reported with rociletinib and has required dose redn., an oral antihyperglycemic, or both, without discontinuation of therapy.  This suggests that patients may be effectively treated chronically for hyperglycemia assocd. with EGFR TKIs targeting T790M, however, guidelines for treatment of hyperglycemia in this setting have not been published.  We discuss mechanisms of hyperglycemia assocd. with TKIs and initial management of hyperglycemia, including benefits and limitations of oral antihyperglycemic options, adjustment of therapy based on grade of hyperglycemia, and recommendations for follow-up glucose monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkySpp7vMZSbVg90H21EOLACvtfcHk0lhLlHzP6nwRNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntV2nu7s%253D&md5=451bfbce8a87320cd07c462e36f8f6b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2218-6751.2015.10.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2218-6751.2015.10.01%26sid%3Dliteratum%253Aachs%26aulast%3DVilladolid%26aufirst%3DJ.%26aulast%3DErsek%26aufirst%3DJ.%2BL.%26aulast%3DFong%26aufirst%3DM.%2BK.%26aulast%3DSirianno%26aufirst%3DL.%26aulast%3DStory%26aufirst%3DE.%2BS.%26atitle%3DManagement%2520of%2520hyperglycemia%2520from%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%2520targeting%2520T790M-mediated%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2015%26volume%3D4%26spage%3D576%26epage%3D583%26doi%3D10.3978%2Fj.issn.2218-6751.2015.10.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Red Brewer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgVZOsdaKhgYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.ejmech.2017.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28526474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=32-47&author=H.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=S.+Surana&title=Recent+updates+on+third+generation+EGFR+inhibitors+and+emergence+of+fourth+generation+EGFR+inhibitors+to+combat+C797S+resistance&doi=10.1016%2Fj.ejmech.2017.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</span></div><div class="casAuthors">Patel, Harun; Pawara, Rahul; Ansari, Azim; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  EGFR T790M mutation leads to resistance to most of clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development, which includes osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  On the other hand recently EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third generation inhibitors.  This review summarizes the third generation inhibitors, synthesis, their mechanism of resistance and latest development on the discovery of a fourth-generation EGFR TKIs and U to Y allosteric strategies to combat the C797S EGFR resistance problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprj-V5hUSHGrVg90H21EOLACvtfcHk0lgVZOsdaKhgYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGmtbo%253D&md5=d0ed35bc7deae5ea37a95910df356c1d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DRecent%2520updates%2520on%2520third%2520generation%2520EGFR%2520inhibitors%2520and%2520emergence%2520of%2520fourth%2520generation%2520EGFR%2520inhibitors%2520to%2520combat%2520C797S%2520resistance%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ejmech.2017.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pferdekamper, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S.</span></span> <span> </span><span class="NLM_article-title">EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1602</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-15-2581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1591-1602&author=Y.+Jiaauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=M.+J.+Niederstauthor=C.+Tompkinsauthor=N.+Timpleauthor=M.+T.+Vaillancourtauthor=A.+C.+Pferdekamperauthor=E.+L.+Lockermanauthor=C.+Liauthor=J.+Andersonauthor=C.+Costaauthor=D.+Liaoauthor=E.+Murphyauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=G.+Lelaisauthor=J.+Barretinaauthor=M.+McNeillauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=N.+Pathanauthor=J.+A.+Engelmanauthor=P.+Y.+Michellysauthor=P.+McNamaraauthor=J.+Harrisauthor=S.+Benderauthor=S.+Kasibhatla&title=EGF816+exerts+anticancer+effects+in+non-small+cell+lung+cancer+by+irreversibly+and+selectively+targeting+primary+and+acquired+activating+mutations+in+the+EGF+receptor&doi=10.1158%2F0008-5472.CAN-15-2581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2581%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DVaillancourt%26aufirst%3DM.%2BT.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKasibhatla%26aufirst%3DS.%26atitle%3DEGF816%2520exerts%2520anticancer%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520by%2520irreversibly%2520and%2520selectively%2520targeting%2520primary%2520and%2520acquired%2520activating%2520mutations%2520in%2520the%2520EGF%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D1591%26epage%3D1602%26doi%3D10.1158%2F0008-5472.CAN-15-2581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27071706" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-generation+inhibitors+targeting+EGFR+T790M+mutation+in+advanced+non-small+cell+lung+cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer</span></div><div class="casAuthors">Wang, Shuhang; Cang, Shundong; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34/1-34/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC).  However, EGFR T790M mutation leads to resistance to most clin. available EGFR TKIs.  Third-generation EGFR TKIs against the T790M mutation have been in active clin. development.  These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775.  Osimertinib and rociletinib have shown clin. efficacy in phase I/II trials in patients who had acquired resistance to first- or second-generation TKIs.  Osimertinib (AZD9291, TAGRISSO) was recently approved by FDA for metastatic EGFR T790M mutation-pos. NSCLC.  HM61713, ASP8237, EGF816, and PF-06747775 are still in early clin. development.  This article reviews the emerging data regarding third-generation agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0o_C9ADDlbVg90H21EOLACvtfcHk0lghfnrD6SojQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnsVChsbg%253D&md5=71185a0816b49a8e578c8563e02e2fa0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-generation%2520inhibitors%2520targeting%2520EGFR%2520T790M%2520mutation%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance</span>. <i>Chin. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1186/s40880-015-0029-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1186%2Fs40880-015-0029-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26152224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVGhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=285-287&author=X.+Xu&title=Parallel+phase+1+clinical+trials+in+the+US+and+in+China%3A+accelerating+the+test+of+avitinib+in+lung+cancer+as+a+novel+inhibitor+selectively+targeting+mutated+EGFR+and+overcoming+T790M-induced+resistance&doi=10.1186%2Fs40880-015-0029-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance</span></div><div class="casAuthors">Xu, Xiao</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">285-287</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clin. trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel.  In the preclin. studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance.  Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clin. trials, and will provide a precision targeted therapy for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryk1A36-5V-7Vg90H21EOLACvtfcHk0lghfnrD6SojQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVGhtw%253D%253D&md5=88ed913733876b7b35f18cc54f19ae73</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Fs40880-015-0029-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40880-015-0029-3%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DX.%26atitle%3DParallel%2520phase%25201%2520clinical%2520trials%2520in%2520the%2520US%2520and%2520in%2520China%253A%2520accelerating%2520the%2520test%2520of%2520avitinib%2520in%2520lung%2520cancer%2520as%2520a%2520novel%2520inhibitor%2520selectively%2520targeting%2520mutated%2520EGFR%2520and%2520overcoming%2520T790M-induced%2520resistance%26jtitle%3DChin.%2520J.%2520Cancer%26date%3D2015%26volume%3D34%26spage%3D285%26epage%3D287%26doi%3D10.1186%2Fs40880-015-0029-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3002</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3002-3019&author=S.+Plankenauthor=D.+C.+Behennaauthor=S.+K.+Nairauthor=T.+O.+Johnsonauthor=A.+Nagataauthor=C.+Almadenauthor=S.+Baileyauthor=T.+E.+Ballardauthor=L.+Bernierauthor=H.+Chengauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=J.+G.+Dealauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+Hemkensauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=J.+Matthewsauthor=B.+W.+Murrayauthor=S.+Niessenauthor=S.+T.+Orrauthor=M.+Pairishauthor=N.+W.+Sachauthor=H.+Shenauthor=M.+Shiauthor=J.+Solowiejauthor=K.+Tranauthor=E.+Tsengauthor=P.+Viciniauthor=Y.+Wangauthor=S.+L.+Weinrichauthor=R.+Zhouauthor=M.+Zientekauthor=L.+Liuauthor=Y.+Luoauthor=S.+Xinauthor=C.+Zhangauthor=J.+Lafontaine&title=Discovery+of+N-%28%283R%2C4R%29-4-Fluoro-1-%286-%28%283-methoxy-1-methyl-1H-pyrazol-4-yl%29amino%29-9-methyl-9H-+purin-2-yl%29pyrrolidine-3-yl%29acrylamide+%28PF-06747775%29+through+structure-based+drug+design%3A+a+high+affinity+irreversible+inhibitor+targeting+oncogenic+EGFR+mutants+with+selectivity+over+wild-type+EGFR&doi=10.1021%2Facs.jmedchem.6b01894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR</span></div><div class="casAuthors">Planken, Simon; Behenna, Douglas C.; Nair, Sajiv K.; Johnson, Theodore O.; Nagata, Asako; Almaden, Chau; Bailey, Simon; Ballard, T. Eric; Bernier, Louise; Cheng, Hengmiao; Cho-Schultz, Sujin; Dalvie, Deepak; Deal, Judith G.; Dinh, Dac M.; Edwards, Martin P.; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle; Kania, Robert S.; Kath, John C.; Matthews, Jean; Murray, Brion W.; Niessen, Sherry; Orr, Suvi T. M.; Pairish, Mason; Sach, Neal W.; Shen, Hong; Shi, Manli; Solowiej, James; Tran, Khanh; Tseng, Elaine; Vicini, Paolo; Wang, Yuli; Weinrich, Scott L.; Zhou, Ru; Zientek, Michael; Liu, Longqing; Luo, Yiqin; Xin, Shuibo; Zhang, Chengyi; Lafontaine, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3002-3019</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC).  Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective.  Secondary oncogenic EGFR mutations account for approx. 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective.  The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.  Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clin. candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties.  Compd. 21 is currently being evaluated in phase-I clin. trials of mutant EGFR driven NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1yLRt7MBSrbVg90H21EOLACvtfcHk0ljK3eU8H6ngKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktFOmtrw%253D&md5=14a6700ed770621bdbd84f7931276f0e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%2BC.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DT.%2BE.%26aulast%3DBernier%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DM.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLafontaine%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520N-%2528%25283R%252C4R%2529-4-Fluoro-1-%25286-%2528%25283-methoxy-1-methyl-1H-pyrazol-4-yl%2529amino%2529-9-methyl-9H-%2520purin-2-yl%2529pyrrolidine-3-yl%2529acrylamide%2520%2528PF-06747775%2529%2520through%2520structure-based%2520drug%2520design%253A%2520a%2520high%2520affinity%2520irreversible%2520inhibitor%2520targeting%2520oncogenic%2520EGFR%2520mutants%2520with%2520selectivity%2520over%2520wild-type%2520EGFR%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3002%26epage%3D3019%26doi%3D10.1021%2Facs.jmedchem.6b01894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lhjI9I3UPvv8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chabon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovejoy, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purcell, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehn, M.</span></span> <span> </span><span class="NLM_article-title">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11815</span>, <span class="refDoi"> DOI: 10.1038/ncomms11815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fncomms11815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27283993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=11815&author=J.+J.+Chabonauthor=A.+D.+Simmonsauthor=A.+F.+Lovejoyauthor=M.+S.+Esfahaniauthor=A.+M.+Newmanauthor=H.+J.+Haringsmaauthor=D.+M.+Kurtzauthor=H.+Stehrauthor=F.+Schererauthor=C.+A.+Karlovichauthor=T.+C.+Hardingauthor=K.+A.+Durkinauthor=G.+A.+Ottersonauthor=W.+T.+Purcellauthor=D.+R.+Camidgeauthor=J.+W.+Goldmanauthor=L.+V.+Sequistauthor=Z.+Piotrowskaauthor=H.+A.+Wakeleeauthor=J.+W.+Nealauthor=A.+A.+Alizadehauthor=M.+Diehn&title=Circulating+tumour+DNA+profiling+reveals+heterogeneity+of+EGFR+inhibitor+resistance+mechanisms+in+lung+cancer+patients&doi=10.1038%2Fncomms11815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients</span></div><div class="casAuthors">Chabon, Jacob J.; Simmons, Andrew D.; Lovejoy, Alexander F.; Esfahani, Mohammad S.; Newman, Aaron M.; Haringsma, Henry J.; Kurtz, David M.; Stehr, Henning; Scherer, Florian; Karlovich, Chris A.; Harding, Thomas C.; Durkin, Kathleen A.; Otterson, Gregory A.; Purcell, W. Thomas; Camidge, D. Ross; Goldman, Jonathan W.; Sequist, Lecia V.; Piotrowska, Zofia; Wakelee, Heather A.; Neal, Joel W.; Alizadeh, Ash A.; Diehn, Maximilian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11815</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Circulating tumor DNA (ctDNA) anal. facilitates studies of tumor heterogeneity.  Here we employ CAPP-Seq ctDNA anal. to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC) patients treated with the third-generation epidermal growth factor receptor (EGFR) inhibitor rociletinib.  We observe multiple resistance mechanisms in 46% of patients after treatment with first-line inhibitors, indicating frequent intra-patient heterogeneity.  Rociletinib resistance recurrently involves MET, EGFR, PIK3CA, ERRB2, KRAS and RB1.  We describe a novel EGFR L798I mutation and find that EGFR C797S, which arises in ∼33% of patients after osimertinib treatment, occurs in <3% after rociletinib.  Increased MET copy no. is the most frequent rociletinib resistance mechanism in this cohort and patients with multiple pre-existing mechanisms (T790M and MET) experience inferior responses.  Similarly, rociletinib-resistant xenografts develop MET amplification that can be overcome with the MET inhibitor crizotinib.  These results underscore the importance of tumor heterogeneity in NSCLC and the utility of ctDNA-based resistance mechanism assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWYkoTWCqiW7Vg90H21EOLACvtfcHk0lhjI9I3UPvv8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslyktro%253D&md5=7ad60e2361497c2e1a992415ccec4e41</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms11815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms11815%26sid%3Dliteratum%253Aachs%26aulast%3DChabon%26aufirst%3DJ.%2BJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DLovejoy%26aufirst%3DA.%2BF.%26aulast%3DEsfahani%26aufirst%3DM.%2BS.%26aulast%3DNewman%26aufirst%3DA.%2BM.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DKurtz%26aufirst%3DD.%2BM.%26aulast%3DStehr%26aufirst%3DH.%26aulast%3DScherer%26aufirst%3DF.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DDurkin%26aufirst%3DK.%2BA.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DPurcell%26aufirst%3DW.%2BT.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DDiehn%26aufirst%3DM.%26atitle%3DCirculating%2520tumour%2520DNA%2520profiling%2520reveals%2520heterogeneity%2520of%2520EGFR%2520inhibitor%2520resistance%2520mechanisms%2520in%2520lung%2520cancer%2520patients%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D11815%26doi%3D10.1038%2Fncomms11815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-123&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De121%26epage%3D123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2eZgx0K8pwmbtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e65</span>– <span class="NLM_lpage">e68</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.12.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2016.12.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28093244" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e65-e68&author=K.+Chenauthor=F.+Zhouauthor=W.+Shenauthor=T.+Jiangauthor=X.+Wuauthor=X.+Tongauthor=Y.+W.+Shaoauthor=S.+Qinauthor=C.+Zhou&title=Novel+mutations+on+EGFR+Leu792+potentially+correlate+to+acquired+resistance+to+osimertinib+in+advanced+NSCLC&doi=10.1016%2Fj.jtho.2016.12.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.12.024%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DNovel%2520mutations%2520on%2520EGFR%2520Leu792%2520potentially%2520correlate%2520to%2520acquired%2520resistance%2520to%2520osimertinib%2520in%2520advanced%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3De65%26epage%3De68%26doi%3D10.1016%2Fj.jtho.2016.12.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2eaaHLDQH-U-MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knebel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, L. F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, A. A.</span></span> <span> </span><span class="NLM_article-title">Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2017.04.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=238-241&author=F.+H.+Knebelauthor=F.+Bettoniauthor=A.+K.+Shimadaauthor=M.+Cruzauthor=J.+V.+Alessiauthor=M.+V.+Negraoauthor=L.+F.+L.+Reisauthor=A.+Katzauthor=A.+A.+Camargo&title=Sequential+liquid+biopsies+reveal+dynamic+alterations+of+EGFR+driver+mutations+and+indicate+EGFR+amplification+as+a+new+mechanism+of+resistance+to+osimertinib+in+NSCLC&doi=10.1016%2Fj.lungcan.2017.04.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DKnebel%26aufirst%3DF.%2BH.%26aulast%3DBettoni%26aufirst%3DF.%26aulast%3DShimada%26aufirst%3DA.%2BK.%26aulast%3DCruz%26aufirst%3DM.%26aulast%3DAlessi%26aufirst%3DJ.%2BV.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DReis%26aufirst%3DL.%2BF.%2BL.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DCamargo%26aufirst%3DA.%2BA.%26atitle%3DSequential%2520liquid%2520biopsies%2520reveal%2520dynamic%2520alterations%2520of%2520EGFR%2520driver%2520mutations%2520and%2520indicate%2520EGFR%2520amplification%2520as%2520a%2520new%2520mechanism%2520of%2520resistance%2520to%2520osimertinib%2520in%2520NSCLC%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D238%26epage%3D241%26doi%3D10.1016%2Fj.lungcan.2017.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2016.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.lungcan.2016.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27393507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=59-61&author=S.+H.+Ouauthor=N.+Agarwalauthor=S.+M.+Ali&title=High+MET+amplification+level+as+a+resistance+mechanism+to+osimertinib+%28AZD9291%29+in+a+patient+that+symptomatically+responded+to+crizotinib+treatment+post-osimertinib+progression&doi=10.1016%2Fj.lungcan.2016.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Agarwal Nikita; Ali Siraj M</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Third-generation EGFR TKI has been approved in the US and EU for the treatment of EGFR mutant T790M+ NSCLC patients that are resistant to first- or second generation EGFR TKIs.  Here we report a patient who developed resistance to osimertinib after a confirmed partial response for 9 months.  Pre-osimertinib and post-osimertinib tumor biopsy revealed the emergence of high level of MET amplification (30 copies) post osimertinib treatment.  Patient was treated with single agent crizotinib, a known MET inhibitor, with transient symptomatic benefit.  MET amplification is one potential resistance mechanism to osimertinib and combination of osimertinib and a MET inhibitor should be investigated post-osimertinib progression in EGFR mutant T790M+ NSCLC patients whose harbored acquired MET amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcGTszAFtshWfpMXQLRstfW6udTcc2eYavwG9RJZHjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7osVSmsA%253D%253D&md5=2cd5da962531483cb3092367da127c64</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2016.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2016.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DAgarwal%26aufirst%3DN.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DHigh%2520MET%2520amplification%2520level%2520as%2520a%2520resistance%2520mechanism%2520to%2520osimertinib%2520%2528AZD9291%2529%2520in%2520a%2520patient%2520that%2520symptomatically%2520responded%2520to%2520crizotinib%2520treatment%2520post-osimertinib%2520progression%26jtitle%3DLung%2520Cancer%26date%3D2016%26volume%3D98%26spage%3D59%26epage%3D61%26doi%3D10.1016%2Fj.lungcan.2016.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loriot, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2073</span>– <span class="NLM_lpage">2078</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1093%2Fannonc%2Fmdv319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26269204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2073-2078&author=D.+Planchardauthor=Y.+Loriotauthor=F.+Andreauthor=A.+Gobertauthor=N.+Augerauthor=L.+Lacroixauthor=J.+C.+Soria&title=EGFR-independent+mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M-positive+NSCLC+patients&doi=10.1093%2Fannonc%2Fmdv319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients</span></div><div class="casAuthors">Planchard D; Loriot Y; Andre F; Gobert A; Auger N; Lacroix L; Soria J C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2073-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD9291 is an oral, irreversible, mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI), which specifically targets both sensitizing and resistant T790M mutations.  This compound has shown outstanding activity, in a phase I/II (AURA) trial.  However, despite impressive tumor responses in T790M-positive patients, acquired resistance to this drug limits the benefit of this compound.  Mutations at the EGFR C797 codon, located within the kinase-binding site, were very recently reported to be a potential mechanism of resistance to AZD9291 in T790M-positive patients.  PATIENTS AND METHODS:  To identify potential mechanisms of resistance to AZD9291, we report here on two patients with resistant biopsy specimens that had been treated with AZD9291.  RESULTS:  We identified in two distinct cases, HER2 and MET amplification by FISH and CGH as a potential mechanism of acquired resistance to third-generation EGFR-TKI.  Interestingly, this event occurred with complete loss of the T790M mutation.  In one case, we observed a different molecular status at two biopsy sites (the T790M mutation at the primary site and wild-type T790M at the metastatic site with different pathways of acquired resistance to AZD9291).  CONCLUSION:  Our observations suggest that T790M-positive and wild-type T790M clones may coexist at baseline.  AZD9291 efficiently suppresses the growth of T790M-positive cells, but a population of wild-type T790M cells at baseline will mediate the development of resistance, here via a by-pass pathway activating either HER2 or MET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS11uv1hoUHSrJzI8owOhpDfW6udTcc2eYavwG9RJZHjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287isVShtw%253D%253D&md5=2cba18208f215fd28fcf58d321d42618</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv319%26sid%3Dliteratum%253Aachs%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DLoriot%26aufirst%3DY.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DGobert%26aufirst%3DA.%26aulast%3DAuger%26aufirst%3DN.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DEGFR-independent%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M-positive%2520NSCLC%2520patients%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2073%26epage%3D2078%26doi%3D10.1093%2Fannonc%2Fmdv319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1744</span>, <span class="refDoi"> DOI: 10.1097/JTO.0000000000000688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1097%2FJTO.0000000000000688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26473643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1736-1744&author=T.+M.+Kimauthor=A.+Songauthor=D.+W.+Kimauthor=S.+Kimauthor=Y.+O.+Ahnauthor=B.+Keamauthor=Y.+K.+Jeonauthor=S.+H.+Leeauthor=D.+H.+Chungauthor=D.+S.+Heo&title=Mechanisms+of+acquired+resistance+to+AZD9291%3A+a+mutation-selective%2C+irreversible+EGFR+inhibitor&doi=10.1097%2FJTO.0000000000000688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor</span></div><div class="casAuthors">Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1736-1744</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFR-mutant non-small-cell lung cancer (NSCLC) who failed prior treatment with EGFR TKIs.  However, acquired resistance to AZD9291 is inevitable.  In this study, we identified the mechanisms of acquired resistance to AZD9291 in EGFR-mutant NSCLC.  Methods: Four NSCLC patients with both an EGFR exon 19 deletion and the EGFR mutation after developing acquired resistance to first-generation EGFR TKIs received AZD9291 at doses of 20 to 80 mg/day in a phase I trial (NCT01802632).  Paired tumor samples before and after treatment were obtained to evaluate EGFR modifications, alternative pathway activation, and histol. transformation.  Genetic alterations were analyzed using Sanger sequencing, fluorescence in situ hybridization, real-time polymerase chain reaction, and targeted exome sequencing.  Results: All four patients achieved a partial response (median duration of response, 9 mo [range, 9-11 mo]) and subsequently showed resistance to AZD9291.  EGFR-mutant clones depopulated AZD9291-resistant tumors to below 1% (baseline, 14%-36%) in three patients with progression: one with the loss of EGFR-double mutant clones and two accompanied by transformation to small-cell carcinoma and focal fibroblast growth factor receptor 1 (FGFR1) amplification, resp.  EGFR-mutant clones remained and the EGFR ligand was overexpressed in one patient with focal progression to AZD9291.  Conclusion: Acquired resistance mechanisms of AZD9291 in patients with EGFR-mutant NSCLC who failed treatment with first-generation EGFR TKIs include the loss of EGFR-mutant clones plus alternative pathway activation or histol. transformation and EGFR ligand-dependent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KLOZPHlkELVg90H21EOLACvtfcHk0lg6e92UEUHhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2it7rE&md5=304e993133713a74dc817f3e05c7e9db</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000688%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BM.%26aulast%3DSong%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DY.%2BO.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DJeon%26aufirst%3DY.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DD.%2BH.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%253A%2520a%2520mutation-selective%252C%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26spage%3D1736%26epage%3D1744%26doi%3D10.1097%2FJTO.0000000000000688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">22005</span>– <span class="NLM_lpage">22015</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.8013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=22005-22015&author=J.+H.+Parkauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=J.+E.+Leeauthor=K.+J.+Sungauthor=S.+Parkauthor=W.+S.+Kimauthor=J.+S.+Songauthor=C.+M.+Choiauthor=Y.+H.+Sungauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=Activation+of+the+IGF1R+pathway+potentially+mediates+acquired+resistance+to+mutant-selective+3rd-generation+EGF+receptor+tyrosine+kinase+inhibitors+in+advanced+non-small+cell+lung+cancer&doi=10.18632%2Foncotarget.8013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8013%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSung%26aufirst%3DK.%2BJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DSung%26aufirst%3DY.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DActivation%2520of%2520the%2520IGF1R%2520pathway%2520potentially%2520mediates%2520acquired%2520resistance%2520to%2520mutant-selective%25203rd-generation%2520EGF%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D22005%26epage%3D22015%26doi%3D10.18632%2Foncotarget.8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span> <span> </span><span class="NLM_article-title">Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">18609</span>– <span class="NLM_lpage">18614</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.14506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.14506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=18609-18614&author=L.+Liauthor=H.+Wangauthor=C.+Liauthor=Z.+Wangauthor=P.+Zhangauthor=X.+Yan&title=Transformation+to+small-cell+carcinoma+as+an+acquired+resistance+mechanism+to+AZD9291%3A+a+case+report&doi=10.18632%2Foncotarget.14506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.14506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.14506%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DX.%26atitle%3DTransformation%2520to%2520small-cell%2520carcinoma%2520as%2520an%2520acquired%2520resistance%2520mechanism%2520to%2520AZD9291%253A%2520a%2520case%2520report%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D18609%26epage%3D18614%26doi%3D10.18632%2Foncotarget.14506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ke, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.tips.2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=887-903&author=E.+E.+Keauthor=Y.+L.+Wu&title=EGFR+as+a+pharmacological+target+in+EGFR-mutant+non-small-cell+lung+cancer%3A+where+do+we+stand+now%3F&doi=10.1016%2Fj.tips.2016.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DKe%26aufirst%3DE.%2BE.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DEGFR%2520as%2520a%2520pharmacological%2520target%2520in%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%253A%2520where%2520do%2520we%2520stand%2520now%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D887%26epage%3D903%26doi%3D10.1016%2Fj.tips.2016.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppert, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmaz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaglowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span> <span> </span><span class="NLM_article-title">Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2294</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1056%2FNEJMoa1400029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24869598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2286-2294&author=J.+A.+Woyachauthor=R.+R.+Furmanauthor=T.+M.+Liuauthor=H.+G.+Ozerauthor=M.+Zapatkaauthor=A.+S.+Ruppertauthor=L.+Xueauthor=D.+H.+Liauthor=S.+M.+Steggerdaauthor=M.+Verseleauthor=S.+S.+Daveauthor=J.+Zhangauthor=A.+S.+Yilmazauthor=S.+M.+Jaglowskiauthor=K.+A.+Blumauthor=A.+Lozanskiauthor=G.+Lozanskiauthor=D.+F.+Jamesauthor=J.+C.+Barrientosauthor=P.+Lichterauthor=S.+Stilgenbauerauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=A.+J.+Johnsonauthor=J.+C.+Byrd&title=Resistance+mechanisms+for+the+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+ibrutinib&doi=10.1056%2FNEJMoa1400029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib</span></div><div class="casAuthors">Woyach, Jennifer A.; Furman, Richard R.; Liu, Ta-Ming; Ozer, Hatice Gulcin; Zapatka, Marc; Ruppert, Amy S.; Xue, Ling; Li, Daniel Hsieh-Hsin; Steggerda, Susanne M.; Versele, Matthias; Dave, Sandeep S.; Zhang, Jenny; Yilmaz, Ayse Selen; Jaglowski, Samantha M.; Blum, Kristie A.; Lozanski, Arletta; Lozanski, Gerard; James, Danelle F.; Barrientos, Jacqueline C.; Lichter, Peter; Stilgenbauer, Stephan; Buggy, Joseph J.; Chang, Betty Y.; Johnson, Amy J.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2286-2294, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL).  Resistance to irreversible kinase inhibitors and resistance assocd. with BTK inhibition have not been characterized.  Although only a small proportion of patients have had a relapse during ibrutinib therapy, an understanding of resistance mechanisms is important.  We evaluated patients with relapsed disease to identify mutations that may mediate ibrutinib resistance.  Methods: We performed whole-exome sequencing at baseline and the time of relapse on samples from six patients with acquired resistance to ibrutinib therapy.  We then performed functional anal. of identified mutations.  In addn., we performed Ion Torrent sequencing for identified resistance mutations on samples from nine patients with prolonged lymphocytosis.  Results: We identified a cysteine-to-serine mutation in BTK at the binding site of ibrutinib in five patients and identified three distinct mutations in PLCγ2 in two patients.  Functional anal. showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib.  The R665W and L845F mutations in PLCγ2 are both potentially gain-of-function mutations that lead to autonomous B-cell-receptor activity.  These mutations were not found in any of the patients with prolonged lymphocytosis who were taking ibrutinib.  Conclusions: Resistance to the irreversible BTK inhibitor ibrutinib often involves mutation of a cysteine residue where ibrutinib binding occurs.  This finding, combined with two addnl. mutations in PLCγ2 that are immediately downstream of BTK, underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrutinib in CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpktSKmZODIjLVg90H21EOLACvtfcHk0ljMJRM5Ovh6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemtrnJ&md5=9eaf9f3ed7518c264b413ef4fe826985</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400029%26sid%3Dliteratum%253Aachs%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DT.%2BM.%26aulast%3DOzer%26aufirst%3DH.%2BG.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DRuppert%26aufirst%3DA.%2BS.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%2BH.%26aulast%3DSteggerda%26aufirst%3DS.%2BM.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DDave%26aufirst%3DS.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYilmaz%26aufirst%3DA.%2BS.%26aulast%3DJaglowski%26aufirst%3DS.%2BM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DLozanski%26aufirst%3DA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DResistance%2520mechanisms%2520for%2520the%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520ibrutinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2286%26epage%3D2294%26doi%3D10.1056%2FNEJMoa1400029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. L.</span></span> <span> </span><span class="NLM_article-title">Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fleu.2014.263" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=895-900&author=S.+Chengauthor=A.+Guoauthor=P.+Luauthor=J.+Maauthor=M.+Colemanauthor=Y.+L.+Wang&title=Functional+characterization+of+BTK%28C481S%29+mutation+that+confers+ibrutinib+resistance%3A+exploration+of+alternative+kinase+inhibitors&doi=10.1038%2Fleu.2014.263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.263%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%2BL.%26atitle%3DFunctional%2520characterization%2520of%2520BTK%2528C481S%2529%2520mutation%2520that%2520confers%2520ibrutinib%2520resistance%253A%2520exploration%2520of%2520alternative%2520kinase%2520inhibitors%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D895%26epage%3D900%26doi%3D10.1038%2Fleu.2014.263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: Emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&author=H.+A.+Yuauthor=S.+K.+Tianauthor=A.+E.+Drilonauthor=L.+Borsuauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+resistance+of+EGFR-mutant+lung+cancer+to+a+T790M-specific+EGFR+inhibitor%3A+Emergence+of+a+third+mutation+%28C797S%29+in+the+EGFR+tyrosine+kinase+domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2eZvqWTA-UGOgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520resistance%2520of%2520EGFR-mutant%2520lung%2520cancer%2520to%2520a%2520T790M-specific%2520EGFR%2520inhibitor%253A%2520Emergence%2520of%2520a%2520third%2520mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DJAMA%2520Oncol.%26date%3D2015%26volume%3D1%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e45</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26749488" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e45-47&author=H.+N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.+L.+Choiauthor=W.+Parkauthor=M.+J.+Ahn&title=Acquired+C797S+mutation+upon+treatment+with+a+T790M-specific+third-generation+EGFR+inhibitor+%28HM61713%29+in+non-small+cell+lung+cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%2BN.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DAcquired%2520C797S%2520mutation%2520upon%2520treatment%2520with%2520a%2520T790M-specific%2520third-generation%2520EGFR%2520inhibitor%2520%2528HM61713%2529%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De45%26epage%3D47%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">JCO2017747576</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28841389" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=JCO2017747576&author=S.+S.+Ramalingamauthor=J.+C.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.+W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+C.+Barrettauthor=K.+S.+Thressauthor=P.+A.+Janne&title=Osimertinib+as+first-line+treatment+of+EGFR+mutation-positive+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520first-line%2520treatment%2520of%2520EGFR%2520mutation-positive%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26spage%3DJCO2017747576%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moores, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushey, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevalier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luistro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brezski, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haytko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neijssen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parren, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. M.</span></span> <span> </span><span class="NLM_article-title">A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">3942</span>– <span class="NLM_lpage">3953</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-15-2833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27216193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=3942-3953&author=S.+L.+Mooresauthor=M.+L.+Chiuauthor=B.+S.+Busheyauthor=K.+Chevalierauthor=L.+Luistroauthor=K.+Dornauthor=R.+J.+Brezskiauthor=P.+Haytkoauthor=T.+Kellyauthor=S.+J.+Wuauthor=P.+L.+Martinauthor=J.+Neijssenauthor=P.+W.+Parrenauthor=J.+Schuurmanauthor=R.+M.+Attarauthor=S.+Laquerreauthor=M.+V.+Lorenziauthor=G.+M.+Anderson&title=A+novel+bispecific+antibody+targeting+EGFR+and+cMet+is+effective+against+EGFR+inhibitor-resistant+lung+tumors&doi=10.1158%2F0008-5472.CAN-15-2833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors</span></div><div class="casAuthors">Moores, Sheri L.; Chiu, Mark L.; Bushey, Barbara S.; Chevalier, Kristen; Luistro, Leopoldo; Dorn, Keri; Brezski, Randall J.; Haytko, Peter; Kelly, Thomas; Wu, Sheng-Jiun; Martin, Pauline L.; Neijssen, Joost; Parren, Paul W. H. I.; Schuurman, Janine; Attar, Ricardo M.; Laquerre, Sylvie; Lorenzi, Matthew V.; Anderson, G. Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3942-3953</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) with activating EGFR mutations become resistant to tyrosine kinase inhibitors (TKI), often through second-site mutations in EGFR (T790M) and/or activation of the cMet pathway.  We engineered a bispecific EGFR-cMet antibody (JNJ-61186372) with multiple mechanisms of action to inhibit primary/secondary EGFR mutations and the cMet pathway.  JNJ-61186372 blocked ligand-induced phosphorylation of EGFR and cMet and inhibited phospho-ERK and phospho-AKT more potently than the combination of single receptor-binding antibodies.  In NSCLC tumor models driven by EGFR and/or cMet, JNJ-61186372 treatment resulted in tumor regression through inhibition of signaling/receptor downmodulation and Fc-driven effector interactions.  Complete and durable regression of human lung xenograft tumors was obsd. with the combination of JNJ-61186372 and a third-generation EGFR TKI.  Interestingly, treatment of cynomolgus monkeys with JNJ-61186372 resulted in no major toxicities, including absence of skin rash obsd. with other EGFR-directed agents.  These results highlight the differentiated potential of JNJ-61186372 to inhibit the spectrum of mutations driving EGFR TKI resistance in NSCLC.  Cancer Res; 76(13); 3942-53. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO31K0yT1EPrVg90H21EOLACvtfcHk0liRH9JVITNKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyit7bE&md5=4af4b3eaf60457ad8b87949556f48397</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2833%26sid%3Dliteratum%253Aachs%26aulast%3DMoores%26aufirst%3DS.%2BL.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DBushey%26aufirst%3DB.%2BS.%26aulast%3DChevalier%26aufirst%3DK.%26aulast%3DLuistro%26aufirst%3DL.%26aulast%3DDorn%26aufirst%3DK.%26aulast%3DBrezski%26aufirst%3DR.%2BJ.%26aulast%3DHaytko%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%2BJ.%26aulast%3DMartin%26aufirst%3DP.%2BL.%26aulast%3DNeijssen%26aufirst%3DJ.%26aulast%3DParren%26aufirst%3DP.%2BW.%26aulast%3DSchuurman%26aufirst%3DJ.%26aulast%3DAttar%26aufirst%3DR.%2BM.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DAnderson%26aufirst%3DG.%2BM.%26atitle%3DA%2520novel%2520bispecific%2520antibody%2520targeting%2520EGFR%2520and%2520cMet%2520is%2520effective%2520against%2520EGFR%2520inhibitor-resistant%2520lung%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D3942%26epage%3D3953%26doi%3D10.1158%2F0008-5472.CAN-15-2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">708</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.12.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.21037%2Ftlcr.2016.12.02" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28149764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=695-708&author=R.+Minariauthor=P.+Bordiauthor=M.+Tiseo&title=Third-generation+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitors+in+T790M-positive+non-small+cell+lung+cancer%3A+review+on+emerged+mechanisms+of+resistance&doi=10.21037%2Ftlcr.2016.12.02"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance</span></div><div class="casAuthors">Minari, Roberta; Bordi, Paola; Tiseo, Marcello</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">695-708</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">A review.  Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-pos. non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib.  Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approx. 10 mo.  Mechanisms detg. progression of disease are heterogeneous and not fully understood.  EGFR-dependent resistance mechanisms (such as new EGFR mutations), bypass pathway activation [as erb-b2 receptor tyrosine kinase 2 (HER2) or MET amplification] and histol. transformation [in small cell lung cancer (SCLC)] have been reported, similarly to previous generation TKIs.  Here, we review principle mechanisms of innate and acquired resistance described in literature both in clin. and preclin. settings during NSCLC treatment with third-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqELenka7GwYrVg90H21EOLACvtfcHk0liRH9JVITNKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSksL8%253D&md5=b40df5074fe4944594507d6f3b4f24dd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.12.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.12.02%26sid%3Dliteratum%253Aachs%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DThird-generation%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitors%2520in%2520T790M-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520review%2520on%2520emerged%2520mechanisms%2520of%2520resistance%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26spage%3D695%26epage%3D708%26doi%3D10.21037%2Ftlcr.2016.12.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niederst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulvey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span> <span> </span><span class="NLM_article-title">The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3924</span>– <span class="NLM_lpage">3933</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F1078-0432.CCR-15-0560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25964297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=3924-3933&author=M.+J.+Niederstauthor=H.+Huauthor=H.+E.+Mulveyauthor=E.+L.+Lockermanauthor=A.+R.+Garciaauthor=Z.+Piotrowskaauthor=L.+V.+Sequistauthor=J.+A.+Engelman&title=The+allelic+context+of+the+C797S+mutation+acquired+upon+treatment+with+third-generation+EGFR+inhibitors+impacts+sensitivity+to+subsequent+treatment+strategies&doi=10.1158%2F1078-0432.CCR-15-0560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies</span></div><div class="casAuthors">Niederst, Matthew J.; Hu, Haichuan; Mulvey, Hillary E.; Lockerman, Elizabeth L.; Garcia, Angel R.; Piotrowska, Zofia; Sequist, Lecia V.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3924-3933</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism in EGFR-mutant adenocarcinomas that have progressed on erlotinib.  Third-generation EGFR inhibitors capable of inhibiting mutant EGFR with T790M produce responses in nearly two thirds of patients.  However, acquired resistance mechanisms in patients treated with these drugs are yet to be described.  Exptl. Design: To study acquired resistance to third-generation EGFR inhibitors, T790M-pos. cells derived from an erlotinib-resistant cancer were made resistant to a third-generation TKI and then characterized using cell and mol. analyses.  Results: Cells resistant to a third-generation TKI acquired an addnl. EGFR mutation, C797S, which prevented suppression of EGFR.  Our results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments.  If the C797S and T790M mutations are in trans, cells will be resistant to third-generation EGFR TKIs, but will be sensitive to a combination of first- and third-generation TKIs.  If the mutations are in cis, no EGFR TKIs alone or in combination can suppress activity.  If C797S develops in cells wild-type for T790 (when third-generation TKIs are administered in the first-line setting), the cells are resistant to third-generation TKIs, but retain sensitivity to first-generation TKIs.  Conclusions: Mutation of C797S in EGFR is a novel mechanism of acquired resistance to third-generation TKIs.  The context in which the C797S develops with respect to the other EGFR alleles affects the efficacy of subsequent treatments.  Clin Cancer Res; 21(17); 3924-33. ©2015 AACR.  See related commentary by Ayeni et al., p. 3818.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwRS-15mDgObVg90H21EOLACvtfcHk0lgxc2NVmH1rKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCrsLfF&md5=47a45613979464e3859c7c3e0538d0f8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0560%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DMulvey%26aufirst%3DH.%2BE.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DGarcia%26aufirst%3DA.%2BR.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520allelic%2520context%2520of%2520the%2520C797S%2520mutation%2520acquired%2520upon%2520treatment%2520with%2520third-generation%2520EGFR%2520inhibitors%2520impacts%2520sensitivity%2520to%2520subsequent%2520treatment%2520strategies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D3924%26epage%3D3933%26doi%3D10.1158%2F1078-0432.CCR-15-0560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han-Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span> <span> </span><span class="NLM_article-title">Brief Report: lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first and third generation EGFR-TKIs and shifts allelic configuration at resistance</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1727</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2017.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.jtho.2017.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28662863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1723-1727&author=Z.+Wangauthor=J.+J.+Yangauthor=J.+Huangauthor=J.+Y.+Yeauthor=X.+C.+Zhangauthor=H.+Y.+Tuauthor=H.+Han-Zhangauthor=Y.+L.+Wu&title=Brief+Report%3A+lung+adenocarcinoma+harboring+EGFR+T790M+and+in+trans+C797S+responds+to+combination+therapy+of+first+and+third+generation+EGFR-TKIs+and+shifts+allelic+configuration+at+resistance&doi=10.1016%2Fj.jtho.2017.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance</span></div><div class="casAuthors">Wang Zhen; Yang Jin-Ji; Huang Jie; Zhang Xu-Chao; Tu Hai-Yan; Ye Jun-Yi; Han-Zhang Han; Wu Yi-Long</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-1727</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S.  In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors.  However, this has not been reported clinically.  METHODS:  We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy.  RESULTS:  At the development of resistance to osimertinib, the patient's plasma sample revealed EGFR C797S located in trans with T790M.  He achieved partial response accompanied by undetectable C797S after commencement of a combinatorial treatment consisting of erlotinib and osimertinib.  After 3 months of progression-free survival, he experienced progressive disease with emergence of EGFR C797S located in cis to T790M.  CONCLUSION:  We report the first clinical evidence of efficacy generated by combination therapy consisting of first- and third-generation EGFR tyrosine kinase inhibitors targeting concomitant EGFR T790M and C797S in trans.  We also reveal that the clonal progression of C797S from in trans to in cis at disease progression may serve as a potential resistance mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKksLRAl4nGUbxh97K6Vt6fW6udTcc2ebLNqA7c2qAqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjjtV2gsw%253D%253D&md5=4a4e858b7e9b39034fd2035da629a88c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2017.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2017.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%2BJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DJ.%2BY.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DTu%26aufirst%3DH.%2BY.%26aulast%3DHan-Zhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BL.%26atitle%3DBrief%2520Report%253A%2520lung%2520adenocarcinoma%2520harboring%2520EGFR%2520T790M%2520and%2520in%2520trans%2520C797S%2520responds%2520to%2520combination%2520therapy%2520of%2520first%2520and%2520third%2520generation%2520EGFR-TKIs%2520and%2520shifts%2520allelic%2520configuration%2520at%2520resistance%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D1723%26epage%3D1727%26doi%3D10.1016%2Fj.jtho.2017.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural pharmacological studies on EGFR T790M/C797S</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.04.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.bbrc.2017.04.138" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2017&pages=266-272&author=L.+L.+Kongauthor=R.+Maauthor=M.+Y.+Yaoauthor=X.+E.+Yanauthor=S.+J.+Zhuauthor=P.+Zhaoauthor=C.+H.+Yun&title=Structural+pharmacological+studies+on+EGFR+T790M%2FC797S&doi=10.1016%2Fj.bbrc.2017.04.138"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.04.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.04.138%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520pharmacological%2520studies%2520on%2520EGFR%2520T790M%252FC797S%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D488%26spage%3D266%26epage%3D272%26doi%3D10.1016%2Fj.bbrc.2017.04.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0likMGgjKHH5fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.canlet.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27840244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=51-54&author=S.+Wangauthor=Y.+Songauthor=D.+Liu&title=EAI045%3A+The+fourth-generation+EGFR+inhibitor+overcoming+T790M+and+C797S+resistance&doi=10.1016%2Fj.canlet.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span></div><div class="casAuthors">Wang, Shuhang; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-54</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M pos. non-small cell lung cancer (NSCLC).  However, resistance develops rapidly.  EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors.  This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2GMAIDfgfeLVg90H21EOLACvtfcHk0lgZHs0qHTyDvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM&md5=e429055412bec2ec2da28b2b959753ae</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEAI045%253A%2520The%2520fourth-generation%2520EGFR%2520inhibitor%2520overcoming%2520T790M%2520and%2520C797S%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D51%26epage%3D54%26doi%3D10.1016%2Fj.canlet.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span> </span><span class="NLM_article-title">Allosteric EGFR inhibitors overcome resistance mutations</span>.  <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">6</span>,  <span class="NLM_fpage">691</span>. DOI: <span class="refDoi"> DOI: 10.1158/2159-8290.CD-RW2016-104</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F2159-8290.CD-RW2016-104" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Allosteric+EGFR+inhibitors+overcome+resistance+mutations.+Cancer+Discovery+2016%2C+6%2C+691.+DOI%3A+10.1158%2F2159-8290.CD-RW2016-104."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-RW2016-104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-RW2016-104%26sid%3Dliteratum%253Aachs%26atitle%3DAllosteric%2520EGFR%2520inhibitors%2520overcome%2520resistance%2520mutations%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D691%26doi%3D10.1158%2F2159-8290.CD-RW2016-104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgZHs0qHTyDvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitor profiling reveals unexpected opportunities to inhibit disease-associated mutant kinases</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">772</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2015.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.celrep.2015.12.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26776524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=772-781&author=K.+C.+Duong-Lyauthor=K.+Devarajanauthor=S.+Liangauthor=K.+Y.+Horiuchiauthor=Y.+Wangauthor=H.+Maauthor=J.+R.+Peterson&title=Kinase+inhibitor+profiling+reveals+unexpected+opportunities+to+inhibit+disease-associated+mutant+kinases&doi=10.1016%2Fj.celrep.2015.12.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Devarajan, Karthik; Liang, Shuguang; Horiuchi, Kurumi Y.; Wang, Yuren; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">772-781</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors have typically been designed to inhibit wild-type kinases rather than the mutant forms that frequently arise in diseases such as cancer.  Mutations can have serious clin. implications by increasing kinase catalytic activity or conferring therapeutic resistance.  To identify opportunities to repurpose inhibitors against disease-assocd. mutant kinases, we conducted a large-scale functional screen of 183 known kinase inhibitors against 76 recombinant mutant kinases.  The results revealed lead compds. with activity against clin. important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for addnl. indications.  Furthermore, using T674I PDGFRα as an example, we show how single-dose screening data can provide predictive structure-activity data to guide subsequent inhibitor optimization.  This study provides a resource for the development of inhibitors against numerous disease-assocd. mutant kinases and illustrates the potential of unbiased profiling as an approach to compd.-centric inhibitor development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXqJUD9YoWLVg90H21EOLACvtfcHk0lhqj5JnE-K9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVaqt7c%253D&md5=b01e8f6ce2aa441400531399d8cf88fc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2015.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2015.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DHoriuchi%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DKinase%2520inhibitor%2520profiling%2520reveals%2520unexpected%2520opportunities%2520to%2520inhibit%2520disease-associated%2520mutant%2520kinases%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26spage%3D772%26epage%3D781%26doi%3D10.1016%2Fj.celrep.2015.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchibori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span> <span> </span><span class="NLM_article-title">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14768</span>, <span class="refDoi"> DOI: 10.1038/ncomms14768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fncomms14768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28287083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14768&author=K.+Uchiboriauthor=N.+Inaseauthor=M.+Arakiauthor=M.+Kamadaauthor=S.+Satoauthor=Y.+Okunoauthor=N.+Fujitaauthor=R.+Katayama&title=Brigatinib+combined+with+anti-EGFR+antibody+overcomes+osimertinib+resistance+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1038%2Fncomms14768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Uchibori, Ken; Inase, Naohiko; Araki, Mitsugu; Kamada, Mayumi; Sato, Shigeo; Okuno, Yasushi; Fujita, Naoya; Katayama, Ryohei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14768</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs).  However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib.  Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance.  In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo.  Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR.  The structure-activity relationship anal. reveals the key component in brigatinib to inhibit the triple-mutant EGFR.  The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression.  Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPEfk1WSIOnLVg90H21EOLACvtfcHk0lhqj5JnE-K9oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXks1GqtL0%253D&md5=4c932113642da4a0190e9fcd00222b6e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fncomms14768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14768%26sid%3Dliteratum%253Aachs%26aulast%3DUchibori%26aufirst%3DK.%26aulast%3DInase%26aufirst%3DN.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DKamada%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26atitle%3DBrigatinib%2520combined%2520with%2520anti-EGFR%2520antibody%2520overcomes%2520osimertinib%2520resistance%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14768%26doi%3D10.1038%2Fncomms14768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koivunen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weremowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butaney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span> <span> </span><span class="NLM_article-title">A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6051</span>– <span class="NLM_lpage">6060</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F0008-5472.CAN-11-1340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6051-6060&author=T.+Sasakiauthor=J.+Koivunenauthor=A.+Oginoauthor=M.+Yanagitaauthor=S.+Nikiforowauthor=W.+Zhengauthor=C.+Lathanauthor=J.+P.+Marcouxauthor=J.+Duauthor=K.+Okudaauthor=M.+Capellettiauthor=T.+Shimamuraauthor=D.+Ercanauthor=M.+Stumpfovaauthor=Y.+Xiaoauthor=S.+Weremowiczauthor=M.+Butaneyauthor=S.+Heonauthor=K.+Wilnerauthor=J.+G.+Christensenauthor=M.+J.+Eckauthor=K.+K.+Wongauthor=N.+Lindemanauthor=N.+S.+Grayauthor=S.+J.+Rodigauthor=P.+A.+Janne&title=A+novel+ALK+secondary+mutation+and+EGFR+signaling+cause+resistance+to+ALK+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-11-1340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1340%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKoivunen%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DYanagita%26aufirst%3DM.%26aulast%3DNikiforow%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DLathan%26aufirst%3DC.%26aulast%3DMarcoux%26aufirst%3DJ.%2BP.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DStumpfova%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DWeremowicz%26aufirst%3DS.%26aulast%3DButaney%26aufirst%3DM.%26aulast%3DHeon%26aufirst%3DS.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520ALK%2520secondary%2520mutation%2520and%2520EGFR%2520signaling%2520cause%2520resistance%2520to%2520ALK%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6051%26epage%3D6060%26doi%3D10.1158%2F0008-5472.CAN-11-1340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockerman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span> <span> </span><span class="NLM_article-title">Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5686</span>– <span class="NLM_lpage">5696</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0ljBRxQfIrUR8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520novel%2520ALK%2520mutations%2520mediate%2520acquired%2520resistance%2520to%2520the%2520next-generation%2520ALK%2520inhibitor%2520alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deryckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayakody, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0ljBRxQfIrUR8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31313</span>– <span class="NLM_lpage">31322</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.18632%2Foncotarget.5182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26375053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31313-31322&author=H.+Wuauthor=A.+Wangauthor=W.+Zhangauthor=B.+Wangauthor=C.+Chenauthor=W.+Wangauthor=C.+Huauthor=Z.+Yeauthor=Z.+Zhaoauthor=L.+Wangauthor=X.+Liauthor=K.+Yuauthor=J.+Liuauthor=J.+Wuauthor=X.+E.+Yanauthor=P.+Zhaoauthor=J.+Wangauthor=C.+Wangauthor=E.+L.+Weisbergauthor=N.+S.+Grayauthor=C.+H.+Yunauthor=J.+Liuauthor=L.+Chenauthor=Q.+Liu&title=Ibrutinib+selectively+and+irreversibly+targets+EGFR+%28L858R%2C+Del19%29+mutant+but+is+moderately+resistant+to+EGFR+%28T790M%29+mutant+NSCLC+cells&doi=10.18632%2Foncotarget.5182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells</span></div><div class="casAuthors">Wu Hong; Wang Aoli; Wang Beilei; Chen Cheng; Wang Wenchao; Hu Chen; Zhao Zheng; Wang Li; Li Xixiang; Yu Kailin; Liu Juan; Wu Jiaxin; Liu Jing; Liu Qingsong; Wu Hong; Wang Aoli; Wu Jiaxin; Liu Qingsong; Zhang Wei; Chen Liang; Ye Zi; Wang Chu; Yan Xiao-E; Zhao Peng; Yun Cai-Hong; Wang Jinhua; Gray Nathanael S; Weisberg Ellen L; Liu Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">31313-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Through comprehensive comparison study, we found that ibrutinib, a clinically approved covalent BTK kinase inhibitor, was highly active against EGFR (L858R, del19) mutant driven NSCLC cells, but moderately active to the T790M 'gatekeeper' mutant cells and not active to wild-type EGFR NSCLC cells.  Ibrutinib strongly affected EGFR mediated signaling pathways and induced apoptosis and cell cycle arrest (G0/G1) in mutant EGFR but not wt EGFR cells.  However, ibrutinib only slowed down tumor progression in PC-9 and H1975 xenograft models.  MEK kinase inhibitor, GSK1120212, could potentiate ibrutinib's effect against the EGFR (L858R/T790M) mutation in vitro but not in vivo.  These results suggest that special drug administration might be required to achieve best clinical response in the ongoing phase I/II clinical trial with ibrutinib for NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaJLK7Cf3HfUQ0lWbKiCflfW6udTcc2eaV47l1pJFpK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283islersw%253D%253D&md5=0b66524bf32eb7fb11ace0b226bbe894</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIbrutinib%2520selectively%2520and%2520irreversibly%2520targets%2520EGFR%2520%2528L858R%252C%2520Del19%2529%2520mutant%2520but%2520is%2520moderately%2520resistant%2520to%2520EGFR%2520%2528T790M%2529%2520mutant%2520NSCLC%2520cells%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D31313%26epage%3D31322%26doi%3D10.18632%2Foncotarget.5182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a novel irreversible EGFR mutant kinase inhibitor with a distinct binding mode</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2944</span>– <span class="NLM_lpage">2962</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2944-2962&author=A.+Wangauthor=X.+Liauthor=H.+Wuauthor=F.+Zouauthor=X.+E.+Yanauthor=C.+Chenauthor=C.+Huauthor=K.+Yuauthor=W.+Wangauthor=P.+Zhaoauthor=J.+Wuauthor=Z.+Qiauthor=W.+Wangauthor=B.+Wangauthor=L.+Wangauthor=T.+Renauthor=S.+Zhangauthor=C.+H.+Yunauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+%28R%29-1-%283-%284-Amino-3-%283-chloro-4-%28pyridin-2-ylmethoxy%29phenyl%29-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-1-yl%29piperidin-1-yl%29prop-2-en-1-one+%28CHMFL-EGFR-202%29+as+a+novel+irreversible+EGFR+mutant+kinase+inhibitor+with+a+distinct+binding+mode&doi=10.1021%2Facs.jmedchem.6b01907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%25284-Amino-3-%25283-chloro-4-%2528pyridin-2-ylmethoxy%2529phenyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-1-yl%2529piperidin-1-yl%2529prop-2-en-1-one%2520%2528CHMFL-EGFR-202%2529%2520as%2520a%2520novel%2520irreversible%2520EGFR%2520mutant%2520kinase%2520inhibitor%2520with%2520a%2520distinct%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2944%26epage%3D2962%26doi%3D10.1021%2Facs.jmedchem.6b01907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollipara, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10909</span>– <span class="NLM_lpage">10912</span>, <span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0lig3ttURDjxLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goettert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schattel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schollmeyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8429</span>– <span class="NLM_lpage">8439</span>, <span class="refDoi"> DOI: 10.1021/jm300852w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300852w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8429-8439&author=R.+Seligauthor=M.+Goettertauthor=V.+Schattelauthor=D.+Schollmeyerauthor=W.+Albrechtauthor=S.+Laufer&title=A+frozen+analogue+approach+to+aminopyridinylimidazoles+leading+to+novel+and+promising+p38+MAP+kinase+inhibitors&doi=10.1021%2Fjm300852w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300852w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300852w%26sid%3Dliteratum%253Aachs%26aulast%3DSelig%26aufirst%3DR.%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DSchollmeyer%26aufirst%3DD.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DA%2520frozen%2520analogue%2520approach%2520to%2520aminopyridinylimidazoles%2520leading%2520to%2520novel%2520and%2520promising%2520p38%2520MAP%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8429%26epage%3D8439%26doi%3D10.1021%2Fjm300852w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10890</span>– <span class="NLM_lpage">10894</span>, <span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2eYTP2div2ooWrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an example of target hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&author=M.+Juchumauthor=M.+Guntherauthor=E.+Doringauthor=A.+Sievers-Englerauthor=M.+Lammerhoferauthor=S.+Laufer&title=Trisubstituted+imidazoles+with+a+rigidized+hinge+binding+motif+act+as+single+digit+nM+inhibitors+of+clinically+relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+mutants%3A+an+example+of+target+hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0li3HmPpnu9WBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DLammerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520imidazoles%2520with%2520a%2520rigidized%2520hinge%2520binding%2520motif%2520act%2520as%2520single%2520digit%2520nM%2520inhibitors%2520of%2520clinically%2520relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520mutants%253A%2520an%2520example%2520of%2520target%2520hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1cnnt1Gruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&author=M.+Guntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+Doringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Doring Eva; Laufer Stefan; Lategahn Jonas; Keul Marina; Engel Julian; Tumbrink Hannah L; Rauh Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by molecular modeling, we synthesized and studied the structure-activity relationship of 40 compounds against clinically relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ6QNTeHCYzDBJ5E29YNGvQfW6udTcc2eZcACFL1U9W97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnnt1Gruw%253D%253D&md5=24b2db3f9206927b546a2a0c8fc05b2a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DDoring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF receptor inhibitors that are selective for the d746-750/T790M/C797S mutant through structure-based de novo design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&author=H.+Parkauthor=H.+Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+receptor+inhibitors+that+are+selective+for+the+d746-750%2FT790M%2FC797S+mutant+through+structure-based+de+novo+design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.%2BY.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520receptor%2520inhibitors%2520that%2520are%2520selective%2520for%2520the%2520d746-750%252FT790M%252FC797S%2520mutant%2520through%2520structure-based%2520de%2520novo%2520design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Callejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrente, M.</span></span> <span> </span><span class="NLM_article-title">Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring</span>. <i>Transl. Lung Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.21037/tlcr.2016.10.07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.21037%2Ftlcr.2016.10.07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=27826527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWrtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=455-465&author=D.+Perez-Callejoauthor=A.+Romeroauthor=M.+Provencioauthor=M.+Torrente&title=Liquid+biopsy+based+biomarkers+in+non-small+cell+lung+cancer+for+diagnosis+and+treatment+monitoring&doi=10.21037%2Ftlcr.2016.10.07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring</span></div><div class="casAuthors">Perez-Callejo, David; Romero, Atocha; Provencio, Mariano; Torrente, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Translational Lung Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">455-465</span>CODEN:
                <span class="NLM_cas:coden">TLCRA9</span>;
        ISSN:<span class="NLM_cas:issn">2226-4477</span>.
    
            (<span class="NLM_cas:orgname">Pioneer Bioscience Publishing Co.</span>)
        </div><div class="casAbstract">Advances in the knowledge of the biol. of non-small cell lung cancer (NSCLC) have revealed mol. information used for systemic cancer therapy targeting metastatic disease, with an important impact on patients overall survival (OS) and quality of life.  However, a biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic.  Moreover, a single biopsy cannot reflect the clonal heterogeneity of the tumor.  The anal. of peripheral blood samples of cancer patients represents a new source of cancer-derived material, known as liq. biopsy, and its components can be obtained from almost all body fluids.  These components have shown to reflect characteristics of the status of both the primary and metastatic diseases, helping the clinicians to move towards a personalized medicine.  The present review focuses on the liq. biopsy components: circulating tumor cells (CTCS), circulating free DNA (cfDNA), exosomes and tumor-educated platelets (TEP); the isolation technologies used and their potential use for non-invasive screening, early diagnosis, prognosis, response to treatment and real time monitoring of the disease, in NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD34ytsPjw3LVg90H21EOLACvtfcHk0liWEtii58FDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWrtL%252FN&md5=131043a2b366887ed55d5e616d52cfe7</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.21037%2Ftlcr.2016.10.07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftlcr.2016.10.07%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Callejo%26aufirst%3DD.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DTorrente%26aufirst%3DM.%26atitle%3DLiquid%2520biopsy%2520based%2520biomarkers%2520in%2520non-small%2520cell%2520lung%2520cancer%2520for%2520diagnosis%2520and%2520treatment%2520monitoring%26jtitle%3DTransl.%2520Lung%2520Cancer%2520Res.%26date%3D2016%26volume%3D5%26spage%3D455%26epage%3D465%26doi%3D10.21037%2Ftlcr.2016.10.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siravegna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span> <span> </span><span class="NLM_article-title">Integrating liquid biopsies into the management of cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2017.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28252003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVSns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=531-548&author=G.+Siravegnaauthor=S.+Marsoniauthor=S.+Sienaauthor=A.+Bardelli&title=Integrating+liquid+biopsies+into+the+management+of+cancer&doi=10.1038%2Fnrclinonc.2017.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating liquid biopsies into the management of cancer</span></div><div class="casAuthors">Siravegna, Giulia; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">531-548</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">During cancer progression and treatment, multiple subclonal populations of tumor cells compete with one another, with selective pressures leading to the emergence of predominant subclones that replicate and spread most proficiently, and are least susceptible to treatment.  At present, the mol. landscapes of solid tumors are established using surgical or biopsy tissue samples.  Tissue-based tumor profiles are, however, subject to sampling bias, provide only a snapshot of tumor heterogeneity, and cannot be obtained repeatedly.  Genomic profiles of circulating cell-free tumor DNA (ctDNA) have been shown to closely match those of the corresponding tumors, with important implications for both mol. pathol. and clin. oncol.  Analyses of circulating nucleic acids, commonly referred to as 'liq. biopsies', can be used to monitor response to treatment, assess the emergence of drug resistance, and quantify minimal residual disease.  In addn. to blood, several other body fluids, such as urine, saliva, pleural effusions, and cerebrospinal fluid, can contain tumor-derived genetic information.  The mol. profiles gathered from ctDNA can be further complemented with those obtained through anal. of circulating tumor cells (CTCs), as well as RNA, proteins, and lipids contained within vesicles, such as exosomes.  In this Review, we examine how different forms of liq. biopsies can be exploited to guide patient care and should ultimately be integrated into clin. practice, focusing on liq. biopsy of ctDNA - arguably the most clin. advanced approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpu8wceypGSLVg90H21EOLACvtfcHk0liWEtii58FDmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVSns7g%253D&md5=b130fd260e8ef3b239229ccd4fbb81bc</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.14%26sid%3Dliteratum%253Aachs%26aulast%3DSiravegna%26aufirst%3DG.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DBardelli%26aufirst%3DA.%26atitle%3DIntegrating%2520liquid%2520biopsies%2520into%2520the%2520management%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D14%26spage%3D531%26epage%3D548%26doi%3D10.1038%2Fnrclinonc.2017.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J. B.</span></span> <span> </span><span class="NLM_article-title">Accessing genetic information with liquid biopsies</span>. <i>Trends Genet.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.tig.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1016%2Fj.tig.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=26450339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjtr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=564-575&author=X.+Caiauthor=F.+Jankuauthor=Q.+Zhanauthor=J.+B.+Fan&title=Accessing+genetic+information+with+liquid+biopsies&doi=10.1016%2Fj.tig.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Accessing Genetic Information with Liquid Biopsies</span></div><div class="casAuthors">Cai, Xuyu; Janku, Filip; Zhan, Qimin; Fan, Jian-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Genetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">564-575</span>CODEN:
                <span class="NLM_cas:coden">TRGEE2</span>;
        ISSN:<span class="NLM_cas:issn">0168-9525</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Recent scientific advances in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a solid foundation for the development of routine mol. liq. biopsies.  This approach provides non-invasive access to genetic information - somatic mutations, epigenetic changes, and differential expression - about the physiol. conditions of the body and diseases.  It opens a valuable avenue for future genetic studies and human disease diagnosis, including prenatal and neurodegenerative disease diagnosis, as well as for cancer screening and monitoring.  With the rapid development of highly sensitive and accurate technologies such as next-generation sequencing, mol. liq. biopsies will quickly become a central piece in the future of precision medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj9lO8vypFNbVg90H21EOLACvtfcHk0livm2dfUzs2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wjtr%252FN&md5=f7350be4f0a941743175b9476080fbf2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.tig.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tig.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DZhan%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DJ.%2BB.%26atitle%3DAccessing%2520genetic%2520information%2520with%2520liquid%2520biopsies%26jtitle%3DTrends%2520Genet.%26date%3D2015%26volume%3D31%26spage%3D564%26epage%3D575%26doi%3D10.1016%2Fj.tig.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oellerich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanzow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walson, P. D.</span></span> <span> </span><span class="NLM_article-title">Using circulating cell-free DNA to monitor personalized cancer therapy</span>. <i>Crit. Rev. Clin. Lab. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1080/10408363.2017.1299683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1080%2F10408363.2017.1299683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28393575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=205-218&author=M.+Oellerichauthor=E.+Schutzauthor=J.+Beckauthor=P.+Kanzowauthor=P.+N.+Plowmanauthor=G.+J.+Weissauthor=P.+D.+Walson&title=Using+circulating+cell-free+DNA+to+monitor+personalized+cancer+therapy&doi=10.1080%2F10408363.2017.1299683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Using circulating cell-free DNA to monitor personalized cancer therapy</span></div><div class="casAuthors">Oellerich, Michael; Schuetz, Ekkehard; Beck, Julia; Kanzow, Philipp; Plowman, Piers N.; Weiss, Glen J.; Walson, Philip D.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Clinical Laboratory Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-218</span>CODEN:
                <span class="NLM_cas:coden">CRCLBH</span>;
        ISSN:<span class="NLM_cas:issn">1040-8363</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">High-quality genomic anal. is crit. for personalized pharmacotherapy in patients with cancer.  Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time mol. monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be esp. useful when tumor tissue is unavailable or insufficient for testing.  For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied.  The US Food and Drug Administration (FDA) recently approved the first such "liq. biopsy" test for EGFR mutations in patients with non-small cell lung cancer (NSCLC).  Such non-invasive methods allow for the identification of specific resistance mutations selected by treatment, such as EGFR T790M, in patients with NSCLC treated with gefitinib.  Chromosomal aberration pattern anal. by low coverage whole genome sequencing is a more universal approach based on genomic instability.  Gains and losses of chromosomal regions have been detected in plasma tumor-specific cfDNA as copy no. aberrations and can be used to compute a genomic copy no. instability (CNI) score of cfDNA.  A specific CNI index obtained by massive parallel sequencing discriminated those patients with prostate cancer from both healthy controls and men with benign prostatic disease.  Furthermore, androgen receptor gene aberrations in cfDNA were assocd. with therapeutic resistance in metastatic castration resistant prostate cancer.  Change in CNI score has been shown to serve as an early predictor of response to std. chemotherapy for various other cancer types (e.g. NSCLC, colorectal cancer, pancreatic ductal adenocarcinomas).  CNI scores have also been shown to predict therapeutic responses to immunotherapy.  Serial genomic profiling can detect resistance mutations up to 16 wk before radiog. progression.  There is a potential for cost savings when ineffective use of expensive new anticancer drugs is avoided or halted.  Challenges for routine implementation of liq. biopsy tests include the necessity of specialized personnel, instrumentation, and software, as well as further development of quality management (e.g. external quality control).  Validation of blood-based tumor genomic profiling in addnl. multicenter outcome studies is necessary; however, cfDNA monitoring can provide clin. important actionable information for precision oncol. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIOOUvcx_lMbVg90H21EOLACvtfcHk0livm2dfUzs2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVGit7o%253D&md5=f4a51703f5787842de448e40595e5f53</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1080%2F10408363.2017.1299683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10408363.2017.1299683%26sid%3Dliteratum%253Aachs%26aulast%3DOellerich%26aufirst%3DM.%26aulast%3DSchutz%26aufirst%3DE.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DKanzow%26aufirst%3DP.%26aulast%3DPlowman%26aufirst%3DP.%2BN.%26aulast%3DWeiss%26aufirst%3DG.%2BJ.%26aulast%3DWalson%26aufirst%3DP.%2BD.%26atitle%3DUsing%2520circulating%2520cell-free%2520DNA%2520to%2520monitor%2520personalized%2520cancer%2520therapy%26jtitle%3DCrit.%2520Rev.%2520Clin.%2520Lab.%2520Sci.%26date%3D2017%26volume%3D54%26spage%3D205%26epage%3D218%26doi%3D10.1080%2F10408363.2017.1299683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovelet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howarth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plagnol, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluthgen, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicotra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auclin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span> <span> </span><span class="NLM_article-title">Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1093%2Fannonc%2Fmdx017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=28104619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A280%3ADC%252BC1c7nsVKjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=784-790&author=J.+Remonauthor=C.+Caramellaauthor=C.+Joveletauthor=L.+Lacroixauthor=A.+Lawsonauthor=S.+Smalleyauthor=K.+Howarthauthor=D.+Galeauthor=E.+Greenauthor=V.+Plagnolauthor=N.+Rosenfeldauthor=D.+Planchardauthor=M.+V.+Bluthgenauthor=A.+Gazzahauthor=C.+Pannetauthor=C.+Nicotraauthor=E.+Auclinauthor=J.+C.+Soriaauthor=B.+Besse&title=Osimertinib+benefit+in+EGFR-mutant+NSCLC+patients+with+T790M-mutation+detected+by+circulating+tumour+DNA&doi=10.1093%2Fannonc%2Fmdx017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA</span></div><div class="casAuthors">Remon J; Planchard D; Bluthgen M V; Gazzah A; Pannet C; Nicotra C; Auclin E; Soria J C; Besse B; Caramella C; Jovelet C; Lacroix L; Lawson A; Smalley S; Howarth K; Gale D; Green E; Plagnol V; Rosenfeld N; Gale D; Rosenfeld N; Rosenfeld N; Soria J C; Besse B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">784-790</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation.  Osimertinib is the standard of care in this situation.  The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients.  Material and methods:  ctDNA T790M mutational status was assessed by Inivata InVision® (eTAm-Seq®) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016.  Progressing T790M-positive NSCLC patients received osimertinib (80 mg daily).  The objectives were to assess the response rate to osimertinib according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, the progression-free survival (PFS) on osimertinib, and the percentage of T790M positive in ctDNA.  Results:  The ctDNA T790M mutation was detected in 50% of NSCLC patients.  Among assessable patients, osimertinib gave a partial response rate of 62.5% and a stable disease rate of 37.5%.  All responses were confirmed responses.  After median follow up of 8 months, median PFS by RECIST criteria was not achieved (95% CI: 4-NA), with 6- and 12-months PFS of 66.7% and 52%, respectively.  Conclusion(s):  ctDNA from liquid biopsy can be used as a surrogate marker for T790M in tumour tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOB3-KrCiLUrP3FVUi_gf8fW6udTcc2ebO_ebzV9ABpbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7nsVKjsg%253D%253D&md5=57f6c1771b8b77f5cb95715dd13d9aac</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx017%26sid%3Dliteratum%253Aachs%26aulast%3DRemon%26aufirst%3DJ.%26aulast%3DCaramella%26aufirst%3DC.%26aulast%3DJovelet%26aufirst%3DC.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DLawson%26aufirst%3DA.%26aulast%3DSmalley%26aufirst%3DS.%26aulast%3DHowarth%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DPlagnol%26aufirst%3DV.%26aulast%3DRosenfeld%26aufirst%3DN.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DBluthgen%26aufirst%3DM.%2BV.%26aulast%3DGazzah%26aufirst%3DA.%26aulast%3DPannet%26aufirst%3DC.%26aulast%3DNicotra%26aufirst%3DC.%26aulast%3DAuclin%26aufirst%3DE.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DBesse%26aufirst%3DB.%26atitle%3DOsimertinib%2520benefit%2520in%2520EGFR-mutant%2520NSCLC%2520patients%2520with%2520T790M-mutation%2520detected%2520by%2520circulating%2520tumour%2520DNA%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D784%26epage%3D790%26doi%3D10.1093%2Fannonc%2Fmdx017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">The clinical development of MEK inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">385</span>– <span class="NLM_lpage">400</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=10.1038%2Fnrclinonc.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=24840079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=385-400&author=Y.+Zhaoauthor=A.+A.+Adjei&title=The+clinical+development+of+MEK+inhibitors&doi=10.1038%2Fnrclinonc.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical development of MEK inhibitors</span></div><div class="casAuthors">Zhao, Yujie; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">385-400</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Aberrant activation of the RAS-RAF-MEK-ERK1/2 pathway occurs in more than 30% of human cancers.  As part of this pathway, MEK1 and MEK2 have crucial roles in tumorigenesis, cell proliferation and inhibition of apoptosis and, therefore, MEK1/2 inhibition is an attractive therapeutic strategy in a no. of cancers.  Highly selective and potent non-ATP-competitive allosteric MEK1/2 inhibitors have been developed and assessed in numerous clin. studies over the past decade.  These agents are not efficacious in a broad range of unselected cancers, although single-agent antitumor activity has been detected mainly in tumors that harbor mutations in genes encoding the members of the RAS and RAF protein families, such as certain melanomas.  Combinations of MEK1/2 inhibitors and cytotoxic chemotherapy, and/or other targeted agents are being studied to expand the efficacy of this class of agents.  Identifying predictive biomarkers, and delineating de novo and acquired resistance mechanisms are essential for the future clin. development of MEK inhibitors.  We discuss the clin. experience with MEK inhibitors to date, and consider the novel approaches to MEK-inhibitor therapy that might improve outcomes and lead to the wider use of such treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjbK3B6OzVbVg90H21EOLACvtfcHk0lhngkYj6uAbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyqtbo%253D&md5=c81e0a5f52a8d4d482b7d617901d67eb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DThe%2520clinical%2520development%2520of%2520MEK%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D385%26epage%3D400%26doi%3D10.1038%2Fnrclinonc.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussenius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defina, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manalo, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span> <span> </span><span class="NLM_article-title">Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.+C.+Manaloauthor=J.+F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+carboxamide-based+allosteric+MEK+inhibitors%3A+discovery+and+optimization+efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0ljjnajfkqAEAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.%2BC.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520carboxamide-based%2520allosteric%2520MEK%2520inhibitors%253A%2520discovery%2520and%2520optimization%2520efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN','PDB','5XGN'); return false;">PDB: 5XGN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D41','PDB','5D41'); return false;">PDB: 5D41</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i14"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01310">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24365"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01310">10.1021/acs.jmedchem.7b01310</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Mechanisms of resistance and results of combination trials (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01310/suppl_file/jm7b01310_si_001.pdf">jm7b01310_si_001.pdf (111.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-10%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01310%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01310" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6019ac7932a9","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
